{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:01:02Z","timestamp":1790010062291,"version":"4.0.1"},"reference-count":266,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National institutes of health, United States","award":["CA288372"],"award-info":[{"award-number":["CA288372"]}]},{"name":"National institutes of health, United States","award":["CA288372"],"award-info":[{"award-number":["CA288372"]}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-22-100-01-1278 CDP"],"award-info":[{"award-number":["RSG-22-100-01-1278 CDP"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02417-4","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T05:32:15Z","timestamp":1754285535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Unraveling the glyco-immunity nexus in pancreatic cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Christabelle","family":"Rajesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2417_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0021-9258(17)46054-6","volume":"2","author":"PA Levene","year":"1906","unstructured":"Levene PA, Alsberg CL. The cleavage products of vitellin. J Biol Chem. 1906;2:127\u201333. https:\/\/doi.org\/10.1016\/S0021-9258(17)46054-6","journal-title":"J Biol Chem"},{"key":"2417_CR2","doi-asserted-by":"publisher","unstructured":"Li W, Li F, Zhang X, Lin H, Xu C. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Signal Transduction and Targeted Therapy. 2021;6:1\u201330. https:\/\/doi.org\/10.1038\/s41392-021-00825-8","DOI":"10.1038\/s41392-021-00825-8"},{"key":"2417_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41419-021-03987-z","volume":"12","author":"G Jiang","year":"2021","unstructured":"Jiang G, Li C, Lu M, Lu K, Li H. Protein lysine crotonylation: past, present, perspective. Cell Death Disease. 2021;12:7. https:\/\/doi.org\/10.1038\/s41419-021-03987-z","journal-title":"Cell Death Disease 2021"},{"key":"2417_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nchembio.495","volume":"7","author":"Z Zhang","year":"2010","unstructured":"Zhang Z, Tan M, Xie Z, Dai L, Chen Y, Zhao Y. Identification of lysine succinylation as a new post-translational modification. Nat Chem Biology. 2010;7:1. https:\/\/doi.org\/10.1038\/nchembio.495","journal-title":"Nat Chem Biology 2010"},{"key":"2417_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20279-w","volume":"12","author":"S Mondal","year":"2021","unstructured":"Mondal S, Wang S, Zheng Y, Sen S, Chatterjee A, Thompson PR. Site-specific incorporation of citrulline into proteins in mammalian cells. Nat Commun. 2021;12:1. https:\/\/doi.org\/10.1038\/s41467-020-20279-w","journal-title":"Nat Commun 2021"},{"key":"2417_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-42025-8","volume":"14","author":"L Sun","year":"2023","unstructured":"Sun L, Zhang Y, Yang B, Sun S, Zhang P, Luo Z, et al. Lactylation of METTL16 promotes Cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer. Nat Commun. 2023;14:1. https:\/\/doi.org\/10.1038\/s41467-023-42025-8","journal-title":"Nat Commun 2023"},{"key":"2417_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41417-024-00729-z","volume":"31","author":"JB Park","year":"2024","unstructured":"Park JB, Moon GH, Cho A, Kwon M, Park JW, Yi EC, et al. Neddylation of insulin receptor substrate acts as a Bona Fide regulator of insulin signaling and its implications for cancer cell migration. Cancer Gene Therapy. 2024;31:4. https:\/\/doi.org\/10.1038\/s41417-024-00729-z","journal-title":"Cancer Gene Therapy 2024"},{"key":"2417_CR8","doi-asserted-by":"publisher","unstructured":"Swatek KN, Komander D. Ubiquitin modifications. Cell Research. 2016;26(4):399\u2013422. https:\/\/doi.org\/10.1038\/cr.2016.39","DOI":"10.1038\/cr.2016.39"},{"key":"2417_CR9","doi-asserted-by":"publisher","unstructured":"Lachiondo-Ortega S, Rejano-Gordillo CM, Simon J, Lopitz-Otsoa F, Delgado C, Mazan-Mamczarz T. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer. Cell Rep. 2024;43. https:\/\/doi.org\/10.1016\/J.CELREP.2024.113924","DOI":"10.1016\/J.CELREP.2024.113924"},{"key":"2417_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-35795-8","volume":"14","author":"JM Lee","year":"2023","unstructured":"Lee JM, Hammar\u00e9n HM, Savitski MM, Baek SH. Control of protein stability by post-translational modifications. Nat Commun. 2023;14:1. https:\/\/doi.org\/10.1038\/s41467-023-35795-8","journal-title":"Nat Commun 2023"},{"key":"2417_CR11","doi-asserted-by":"publisher","unstructured":"Tan CSH, Bodenmiller B, Pasculescu A, Jovanovic M, Hengartner MO, Claus J et al. Comparative analysis reveals conserved protein phosphorylation networks implicated in multiple diseases. Sci Signal 2009;2. https:\/\/doi.org\/10.1126\/SCISIGNAL.2000316\/SUPPL_FILE\/2_RA39_SM.PDF","DOI":"10.1126\/SCISIGNAL.2000316\/SUPPL_FILE\/2_RA39_SM.PDF"},{"key":"2417_CR12","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1126\/SCIENCE.1172867\/SUPPL_FILE\/HOLT-SOM.PDF","volume":"325","author":"LJ Holt","year":"2009","unstructured":"Holt LJ, Tuch BB, Villen J, Johnson AD, Gygi SP, Morgan DO. Global analysis of cdk1 substrate phosphorylation sites provides insiqhts into evolution. Sci (1979). 2009;325:1682\u20136. https:\/\/doi.org\/10.1126\/SCIENCE.1172867\/SUPPL_FILE\/HOLT-SOM.PDF","journal-title":"Sci (1979)"},{"key":"2417_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2012.05.036","volume":"150","author":"P Beltrao","year":"2012","unstructured":"Beltrao P, Alban\u00e8se V, Kenner LR, Swaney DL, Burlingame A, Vill\u00e9n J, et al. Systematic functional prioritization of protein posttranslational modifications. Cell. 2012;150:413\u201325. https:\/\/doi.org\/10.1016\/j.cell.2012.05.036","journal-title":"Cell"},{"key":"2417_CR14","doi-asserted-by":"publisher","unstructured":"Demel UM, B\u00f6ger M, Yousefian S, Grunert C, Zhang L, Hotz PW, et al. Activated sumoylation restricts MHC class I antigen presentation to confer immune evasion in cancer. J Clin Invest. 2022;132. https:\/\/doi.org\/10.1172\/JCI152383","DOI":"10.1172\/JCI152383"},{"key":"2417_CR15","doi-asserted-by":"publisher","unstructured":"Liu Y, Feng W, Wang Y, Wu B. Crosstalk between protein post-translational modifications and phase separation. Cell Communication and Signaling. 2024 22:1 2024;22:1\u201315. https:\/\/doi.org\/10.1186\/S12964-023-01380-1","DOI":"10.1186\/S12964-023-01380-1"},{"key":"2417_CR16","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/J.BBAGEN.2012.09.014","volume":"1820","author":"KTBG Schjoldager","year":"2012","unstructured":"Schjoldager KTBG, Clausen H. Site-specific protein O-glycosylation modulates proprotein processing \u2014 Deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochimica et biophysica acta (BBA) -. Gen Subj. 2012;1820:2079\u201394. https:\/\/doi.org\/10.1016\/J.BBAGEN.2012.09.014","journal-title":"Gen Subj"},{"key":"2417_CR17","doi-asserted-by":"publisher","first-page":"e202300392","DOI":"10.1002\/CHEM.202300392","volume":"29","author":"S Behren","year":"2023","unstructured":"Behren S, Schorlemer M, Schmidt G, Aktories K, Westerlind U. Antibodies directed against GalNAc- and GlcNAc-O-Tyrosine posttranslational Modifications\u2013 a new tool for glycoproteomic detection. Chem\u2013 Eur J. 2023;29:e202300392. https:\/\/doi.org\/10.1002\/CHEM.202300392","journal-title":"Chem\u2013 Eur J"},{"key":"2417_CR18","doi-asserted-by":"publisher","first-page":"1240115","DOI":"10.3389\/FONC.2023.1240115\/BIBTEX","volume":"13","author":"H Dutta","year":"2023","unstructured":"Dutta H, Jain N. Post-translational modifications and their implications in cancer. Front Oncol. 2023;13:1240115. https:\/\/doi.org\/10.3389\/FONC.2023.1240115\/BIBTEX","journal-title":"Front Oncol"},{"key":"2417_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ccell.2019.06.006","volume":"36","author":"S Mereiter","year":"2019","unstructured":"Mereiter S, Balma\u00f1a M, Campos D, Gomes J, Reis CA. Glycosylation in the era of Cancer-Targeted therapy: where are we heading?? Cancer Cell. 2019;36:6\u201316. https:\/\/doi.org\/10.1016\/j.ccell.2019.06.006","journal-title":"Cancer Cell"},{"key":"2417_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.trecan.2020.04.002","volume":"6","author":"AF Costa","year":"2020","unstructured":"Costa AF, Campos D, Reis CA, Gomes C. Targeting glycosylation: A new road for Cancer drug discovery. Trends Cancer. 2020;6:757\u201366. https:\/\/doi.org\/10.1016\/j.trecan.2020.04.002","journal-title":"Trends Cancer"},{"key":"2417_CR21","doi-asserted-by":"publisher","first-page":"102935","DOI":"10.1016\/J.JBC.2023.102935","volume":"299","author":"A Purushothaman","year":"2023","unstructured":"Purushothaman A, Mohajeri M, Lele TP. The role of glycans in the mechanobiology of cancer. J Biol Chem. 2023;299:102935. https:\/\/doi.org\/10.1016\/J.JBC.2023.102935","journal-title":"J Biol Chem"},{"key":"2417_CR22","doi-asserted-by":"publisher","first-page":"188464","DOI":"10.1016\/J.BBCAN.2020.188464","volume":"1875","author":"D Thomas","year":"2021","unstructured":"Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer. 2021;1875:188464. https:\/\/doi.org\/10.1016\/J.BBCAN.2020.188464","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2417_CR23","doi-asserted-by":"publisher","first-page":"460344","DOI":"10.3389\/FONC.2019.00380\/BIBTEX","volume":"9","author":"A Peixoto","year":"2019","unstructured":"Peixoto A, Relvas-Santos M, Azevedo R, Lara Santos L, Ferreira JA. Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks. Front Oncol. 2019;9:460344. https:\/\/doi.org\/10.3389\/FONC.2019.00380\/BIBTEX","journal-title":"Front Oncol"},{"key":"2417_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41388-023-02702-w","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Chen H. Protein glycosylation alterations in hepatocellular carcinoma: function and clinical implications. Oncogene. 2023;42:24. https:\/\/doi.org\/10.1038\/s41388-023-02702-w","journal-title":"Oncogene 2023"},{"key":"2417_CR25","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.3390\/CANCERS15143536","volume":"15","author":"Y Matsumoto","year":"2023","unstructured":"Matsumoto Y, Ju T. Aberrant glycosylation as immune therapeutic targets for solid tumors. Cancers. 2023;15:15:3536. https:\/\/doi.org\/10.3390\/CANCERS15143536","journal-title":"Page 3536"},{"key":"2417_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Reviews Disease Primers. 2016;2:1. https:\/\/doi.org\/10.1038\/nrdp.2016.22","journal-title":"Nat Reviews Disease Primers 2016"},{"key":"2417_CR27","unstructured":"PDQ Adult Treatment Editorial Board. Pancreatic Cancer Treatment (Adult) (PDQ\u00ae): Patient Version. PDQ Cancer Information Summaries 2002."},{"key":"2417_CR28","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/J.CELL.2020.03.062\/ATTACHMENT\/C6A81FF6-F4F0-497B-A89A-AA7DE5917E48\/MMC6.XLSX","volume":"181","author":"KM Chung","year":"2020","unstructured":"Chung KM, Singh J, Lawres L, Dorans KJ, Garcia C, Burkhardt DB, et al. Endocrine-Exocrine signaling drives Obesity-Associated pancreatic ductal adenocarcinoma. Cell. 2020;181:832\u201347. https:\/\/doi.org\/10.1016\/J.CELL.2020.03.062\/ATTACHMENT\/C6A81FF6-F4F0-497B-A89A-AA7DE5917E48\/MMC6.XLSX..e18.","journal-title":"Cell"},{"key":"2417_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cmet.2019.07.003","volume":"30","author":"AMY Zhang","year":"2019","unstructured":"Zhang AMY, Magrill J, de Winter TJJ, Hu X, Skovs\u00f8 S, Schaeffer DF, et al. Endogenous hyperinsulinemia contributes to pancreatic Cancer development. Cell Metab. 2019;30:403\u20134. https:\/\/doi.org\/10.1016\/j.cmet.2019.07.003","journal-title":"Cell Metab"},{"key":"2417_CR30","unstructured":"Survival Rates for Pancreatic Cancer| American Cancer Society n. d. https:\/\/www.cancer.org\/cancer\/types\/pancreatic-cancer\/detection-diagnosis-staging\/survival-rates.html (accessed May 5, 2024)."},{"key":"2417_CR31","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/CNCR.22852","volume":"110","author":"KY Bilimoria","year":"2007","unstructured":"Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, et al. Validation of the 6th edition AJCC pancreatic cancer staging system. Cancer. 2007;110:738\u201344. https:\/\/doi.org\/10.1002\/CNCR.22852","journal-title":"Cancer"},{"key":"2417_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/J.1365-2036.2006.02961.X","volume":"24","author":"YH Shaib","year":"2006","unstructured":"Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the united states: changes below the surface. Aliment Pharmacol Ther. 2006;24:87\u201394. https:\/\/doi.org\/10.1111\/J.1365-2036.2006.02961.X","journal-title":"Aliment Pharmacol Ther"},{"key":"2417_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X13478680","volume":"6","author":"PE Oberstein","year":"2013","unstructured":"Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Th Adv Gastroenterol. 2013;6:321. https:\/\/doi.org\/10.1177\/1756283X13478680","journal-title":"Th Adv Gastroenterol"},{"key":"2417_CR34","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/SCIENCE.1171362\/SUPPL_FILE","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Sci (1979). 2009;324:1457\u201361. https:\/\/doi.org\/10.1126\/SCIENCE.1171362\/SUPPL_FILE\/OLIVE-SOM.PDF.","journal-title":"Sci (1979)"},{"key":"2417_CR35","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1158\/1078-0432.CCR-09-0414\/346870\/","volume":"15","author":"G Komar","year":"2009","unstructured":"Komar G, Kauhanen S, Liukko K, Sepp\u00e4nen M, Kajander S, Ovaska J, et al. Decreased blood flow with increased metabolic activity: A novel sign of pancreatic tumor aggressiveness. Clin Cancer Res. 2009;15:5511\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0414\/346870\/. P\/DECREASED-BLOOD-FLOW-WITH-INCREASED-METABOLIC","journal-title":"Clin Cancer Res"},{"key":"2417_CR36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","volume":"21","author":"LJ Bayne","year":"2012","unstructured":"Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. Tumor-Derived Granulocyte-Macrophage Colony-Stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic Cancer. Cancer Cell. 2012;21:822\u201335. https:\/\/doi.org\/10.1016\/j.ccr.2012.04.025","journal-title":"Cancer Cell"},{"key":"2417_CR37","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-Induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012;21:836\u201347. https:\/\/doi.org\/10.1016\/j.ccr.2012.04.024","journal-title":"Cancer Cell"},{"key":"2417_CR38","doi-asserted-by":"publisher","unstructured":"Hingorani SR. Epithelial and stromal co-evolution and complicity in pancreatic cancer. Nature Reviews Cancer 2022;23(2):57\u201377. https:\/\/doi.org\/10.1038\/s41568-022-00530-w","DOI":"10.1038\/s41568-022-00530-w"},{"key":"2417_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-27896-z","volume":"13","author":"SP Pothapragada","year":"2022","unstructured":"Pothapragada SP, Gupta P, Mukherjee S, Das T. Matrix mechanics regulates epithelial defence against cancer by tuning dynamic localization of filamin. Nat Commun. 2022;13:1. https:\/\/doi.org\/10.1038\/s41467-021-27896-z","journal-title":"Nat Commun 2022"},{"key":"2417_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/J.SEMCANCER.2019.05.011","volume":"63","author":"N Tanimura","year":"2020","unstructured":"Tanimura N, Fujita Y. Epithelial defense against cancer (EDAC). Semin Cancer Biol. 2020;63:44\u20138. https:\/\/doi.org\/10.1016\/J.SEMCANCER.2019.05.011","journal-title":"Semin Cancer Biol"},{"key":"2417_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/ncb3509","volume":"2017 19","author":"S Kon","year":"2017","unstructured":"Kon S, Ishibashi K, Katoh H, Kitamoto S, Shirai T, Tanaka S, et al. Cell competition with normal epithelial cells promotes apical extrusion of transformed cells through metabolic changes. Nat Cell Biol. 2017;2017 19:5. https:\/\/doi.org\/10.1038\/ncb3509","journal-title":"Nat Cell Biol"},{"key":"2417_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/GAD.275776.115","volume":"30","author":"H Ying","year":"2016","unstructured":"Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355\u201385. https:\/\/doi.org\/10.1101\/GAD.275776.115","journal-title":"Genes Dev"},{"key":"2417_CR43","doi-asserted-by":"publisher","unstructured":"Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012;142. https:\/\/doi.org\/10.1053\/J.GASTRO.2011.12.042","DOI":"10.1053\/J.GASTRO.2011.12.042"},{"key":"2417_CR44","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nat. 2015;518:7540. https:\/\/doi.org\/10.1038\/nature14169","journal-title":"Nat 2015"},{"key":"2417_CR45","doi-asserted-by":"publisher","unstructured":"Bulle A, Lim KH. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal transduction and targeted therapy. 2020;5:1\u201312. https:\/\/doi.org\/10.1038\/s41392-020-00341-1","DOI":"10.1038\/s41392-020-00341-1"},{"key":"2417_CR46","doi-asserted-by":"publisher","unstructured":"Amaral MJ, Amaral M, Freitas J, Oliveira RC, Ser\u00f4dio M, Cipriano MA, et al. Tumor stroma area and other prognostic factors in pancreatic ductal adenocarcinoma patients submitted to surgery. Diagnostics. 2023;13. https:\/\/doi.org\/10.3390\/DIAGNOSTICS13040655\/S1","DOI":"10.3390\/DIAGNOSTICS13040655\/S1"},{"key":"2417_CR47","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/S12672-023-00744-W","volume":"14","author":"M Lu","year":"2023","unstructured":"Lu M, Zou Y, Fu P, Li Y, Wang P, Li G, et al. The tumor\u2013stroma ratio and the immune microenvironment improve the prognostic prediction of pancreatic ductal adenocarcinoma. Discover Oncol. 2023;14:124. https:\/\/doi.org\/10.1007\/S12672-023-00744-W","journal-title":"Discover Oncol"},{"key":"2417_CR48","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","volume":"18","author":"C Feig","year":"2012","unstructured":"Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas Cancer microenvironment. Clin Cancer Res. 2012;18:4266\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3114","journal-title":"Clin Cancer Res"},{"key":"2417_CR49","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/NRM3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786\u2013801. https:\/\/doi.org\/10.1038\/NRM3904","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2417_CR50","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1053\/j.gastro.2004.12.036","volume":"128","author":"MG Bachem","year":"2005","unstructured":"Bachem MG, Sch\u00fcnemann M, Ramadani M, Siech M, Beger H, Buck A, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128:907\u201321. https:\/\/doi.org\/10.1053\/j.gastro.2004.12.036","journal-title":"Gastroenterology"},{"key":"2417_CR51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00006676-200411000-00003","volume":"29","author":"CE Binkley","year":"2004","unstructured":"Binkley CE, Zhang L, Greenson JK, Giordano TJ, Kuick R, Misek D, et al. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas. 2004;29:254\u201363. https:\/\/doi.org\/10.1097\/00006676-200411000-00003","journal-title":"Pancreas"},{"key":"2417_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Reviews Gastroenterol Hepatol. 2020;17:8. https:\/\/doi.org\/10.1038\/s41575-020-0300-1","journal-title":"Nat Reviews Gastroenterol Hepatol 2020"},{"key":"2417_CR53","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.cmet.2019.02.005","volume":"29","author":"CM Hu","year":"2019","unstructured":"Hu CM, Tien SC, Hsieh PK, Jeng YM, Chang MC, Chang YT, et al. High glucose triggers nucleotide imbalance through O-GlcNAcylation of key enzymes and induces KRAS mutation in pancreatic cells. Cell Metab. 2019;29:1334\u2013e134910. https:\/\/doi.org\/10.1016\/j.cmet.2019.02.005","journal-title":"Cell Metab"},{"key":"2417_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12915-019-0671-3","volume":"17","author":"NM Akella","year":"2019","unstructured":"Akella NM, Ciraku L, Reginato MJ. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biology. 2019;17:1. https:\/\/doi.org\/10.1186\/S12915-019-0671-3","journal-title":"BMC Biology 2019"},{"key":"2417_CR55","doi-asserted-by":"publisher","unstructured":"Kim PK, Halbrook CJ, Kerk SA, Radyk M, Wisner S, Kremer DM et al. Hyaluronic acid fuels pancreatic cancer cell growth. Elife 2021;10. https:\/\/doi.org\/10.7554\/ELIFE.62645","DOI":"10.7554\/ELIFE.62645"},{"key":"2417_CR56","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/J.MOLONC.2014.12.013","volume":"9","author":"IO Potapenko","year":"2015","unstructured":"Potapenko IO, L\u00fcders T, Russnes HG, Helland \u00c5, S\u00f8rlie T, Kristensen VN, et al. Glycan-related gene expression signatures in breast cancer subtypes; relation to survival. Mol Oncol. 2015;9:861\u201376. https:\/\/doi.org\/10.1016\/J.MOLONC.2014.12.013","journal-title":"Mol Oncol"},{"key":"2417_CR57","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1158\/1078-0432.CCR-17-3533\/73859\/","volume":"24","author":"M Noda","year":"2018","unstructured":"Noda M, Okayama H, Tachibana K, Sakamoto W, Saito K, Min AKT, et al. Glycosyltransferase gene expression identifies a poor prognostic colorectal cancer subtype associated with mismatch repair deficiency and incomplete glycan synthesis. Clin Cancer Res. 2018;24:4468\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3533\/73859\/. AM\/GLYCOSYLTRANSFERASE-GENE-EXPRESSION-IDENTIFIES-A","journal-title":"Clin Cancer Res"},{"key":"2417_CR58","doi-asserted-by":"publisher","first-page":"109037","DOI":"10.1016\/J.ISCI.2024.109037\/ATTACHMENT\/EC4ADF7C-6842-449E-A056-20EDB625C02C\/MMC4","volume":"27","author":"E Rodriguez","year":"2024","unstructured":"Rodriguez E, Lindijer DV, van Vliet SJ, Garcia Vallejo JJ, van Kooyk Y. The transcriptional landscape of glycosylation-related genes in cancer. IScience. 2024;27:109037. https:\/\/doi.org\/10.1016\/J.ISCI.2024.109037\/ATTACHMENT\/EC4ADF7C-6842-449E-A056-20EDB625C02C\/MMC4","journal-title":"IScience"},{"key":"2417_CR59","doi-asserted-by":"publisher","unstructured":"Mohamed Abd-El-Halim Y, El Kaoutari A, Silvy F, Rubis M, Bigonnet M, Roques J et al. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. EBioMedicine 2021;71. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103541","DOI":"10.1016\/j.ebiom.2021.103541"},{"key":"2417_CR60","doi-asserted-by":"publisher","unstructured":"Rodriguez E, Boelaars K, Brown K, Maduni\u0107 K, van Ee T, Dijk F et al. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Commun Biology 2022;5:1\u201315. https:\/\/doi.org\/10.1038\/s42003-021-02934-0","DOI":"10.1038\/s42003-021-02934-0"},{"key":"2417_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/BS.ACR.2016.11.009","volume":"134","author":"RR Drake","year":"2016","unstructured":"Drake RR, Powers TW, Jones EE, Bruner E, Mehta AS, Angel PM. MALDI mass spectrometry imaging of N-linked glycans in cancer tissues. Adv Cancer Res. 2016;134:85. https:\/\/doi.org\/10.1016\/BS.ACR.2016.11.009","journal-title":"Adv Cancer Res"},{"key":"2417_CR62","doi-asserted-by":"publisher","unstructured":"Lumibao JC, Tremblay JR, Hsu J, Engle DD. Altered glycosylation in pancreatic cancer and beyond. J Exp Med. 2022;219. https:\/\/doi.org\/10.1084\/JEM.20211505\/213200","DOI":"10.1084\/JEM.20211505\/213200"},{"key":"2417_CR63","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3892\/OL.2019.9885","volume":"17","author":"J Munkley","year":"2019","unstructured":"Munkley J. The glycosylation landscape of pancreatic cancer. Oncol Lett. 2019;17:2569. https:\/\/doi.org\/10.3892\/OL.2019.9885","journal-title":"Oncol Lett"},{"key":"2417_CR64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/BS.ACR.2022.07.003","volume":"157","author":"MP Marciel","year":"2023","unstructured":"Marciel MP, Haldar B, Hwang J, Bhalerao N, Bellis SL. Role of tumor cell sialylation in pancreatic cancer progression. Adv Cancer Res. 2023;157:123\u201355. https:\/\/doi.org\/10.1016\/BS.ACR.2022.07.003","journal-title":"Adv Cancer Res"},{"key":"2417_CR65","doi-asserted-by":"publisher","first-page":"16613","DOI":"10.1073\/PNAS.262438199\/ASSET\/E7D75E83-13F7-4461-A8AA-B2B085A2E14B","volume":"99","author":"T Ju","year":"2002","unstructured":"Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 \u03b2-galactosyltransferase. Proc Natl Acad Sci U S A. 2002;99:16613\u20138. https:\/\/doi.org\/10.1073\/PNAS.262438199\/ASSET\/E7D75E83-13F7-4461-A8AA-B2B085A2E14B\/ASSETS\/GRAPHIC\/PQ2624381004.JPEG.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR66","doi-asserted-by":"publisher","first-page":"E4066","DOI":"10.1073\/PNAS.1406619111\/SUPPL_FILE","volume":"111","author":"P Radhakrishnan","year":"2014","unstructured":"Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci U S A. 2014;111:E4066\u201375. https:\/\/doi.org\/10.1073\/PNAS.1406619111\/SUPPL_FILE\/PNAS.1406619111.SAPP.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR67","doi-asserted-by":"publisher","unstructured":"Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC et al. A mutant cheperone converts a wild-type protein into a tumor-specific antigen. Science (1979) 2006;314:304\u20138. https:\/\/doi.org\/10.1126\/SCIENCE.1129200\/SUPPL_FILE\/SCHIETINGER.SOM.PDF","DOI":"10.1126\/SCIENCE.1129200\/SUPPL_FILE\/SCHIETINGER.SOM.PDF"},{"key":"2417_CR68","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/GLYCOB\/CWR182","volume":"22","author":"EP Bennett","year":"2012","unstructured":"Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012;22:736\u201356. https:\/\/doi.org\/10.1093\/GLYCOB\/CWR182","journal-title":"Glycobiology"},{"key":"2417_CR69","doi-asserted-by":"publisher","unstructured":"Bordron A, Morel M, Bagacean C, Dueymes M, Pochard P, Harduin-Lepers A, et al. Hyposialylation must be considered to develop future therapies in autoimmune diseases. Int J Mol Sci. 2021;22:22:3402. https:\/\/doi.org\/10.3390\/IJMS22073402","DOI":"10.3390\/IJMS22073402"},{"key":"2417_CR70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/GLYCOB\/6.7.647","volume":"6","author":"S Tsuji","year":"1996","unstructured":"Tsuji S, Datta AK, Paulson JC. Letters to the Glyco-Forum: systematic nomenclature for sialyltransferases. Glycobiology. 1996;6:647\u2013647. https:\/\/doi.org\/10.1093\/GLYCOB\/6.7.647","journal-title":"Glycobiology"},{"key":"2417_CR71","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1083\/JCB.200711151","volume":"182","author":"T Ju","year":"2008","unstructured":"Ju T, Aryal RP, Stowell CJ, Cummings RD. Regulation of protein O-glycosylation by the Endoplasmic reticulum\u2013localized molecular chaperone Cosmc. J Cell Biol. 2008;182:531. https:\/\/doi.org\/10.1083\/JCB.200711151","journal-title":"J Cell Biol"},{"key":"2417_CR72","doi-asserted-by":"publisher","first-page":"1093496","DOI":"10.93496\/BIBTEX","volume":"12","author":"C Rajesh","year":"2023","unstructured":"Rajesh C, Radhakrishnan P. The (Sialyl) Tn antigen: contributions to immunosuppression in Gastrointestinal cancers. Front Oncol. 2023;12:1093496. https:\/\/doi.org\/10.3389\/FONC.2022.1093496\/BIBTEX","journal-title":"Front Oncol"},{"key":"2417_CR73","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.1158\/0008-5472.CAN-04-1921","volume":"64","author":"NT Marcos","year":"2004","unstructured":"Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the Cancer-Associated Sialyl-Tn antigen. Cancer Res. 2004;64:7050\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1921","journal-title":"Cancer Res"},{"key":"2417_CR74","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0300-9084(01)01301-3","volume":"83","author":"A Harduin-Lepers","year":"2001","unstructured":"Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie. 2001;83:727\u201337. https:\/\/doi.org\/10.1016\/S0300-9084(01)01301-3","journal-title":"Biochimie"},{"key":"2417_CR75","doi-asserted-by":"publisher","first-page":"6885","DOI":"10.1111\/JCMM.14572","volume":"23","author":"D Thomas","year":"2019","unstructured":"Thomas D, Sagar S, Caffrey T, Grandgenett PM, Radhakrishnan P. Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells. J Cell Mol Med. 2019;23:6885\u201396. https:\/\/doi.org\/10.1111\/JCMM.14572","journal-title":"J Cell Mol Med"},{"key":"2417_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12943-015-0386-1\/FIGURES\/5","volume":"14","author":"BT Hofmann","year":"2015","unstructured":"Hofmann BT, Schl\u00fcter L, Lange P, Mercanoglu B, Ewald F, F\u00f6lster A, et al. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer. 2015;14:1\u201315. https:\/\/doi.org\/10.1186\/S12943-015-0386-1\/FIGURES\/5","journal-title":"Mol Cancer"},{"key":"2417_CR77","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1053\/j.gastro.2018.08.007","volume":"155","author":"S Chugh","year":"2018","unstructured":"Chugh S, Barkeer S, Rachagani S, Nimmakayala RK, Perumal N, Pothuraju R, et al. Disruption of C1galt1 gene promotes development and metastasis of pancreatic adenocarcinomas in mice. Gastroenterology. 2018;155:1608\u201324. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.007","journal-title":"Gastroenterology"},{"key":"2417_CR78","first-page":"354","volume":"53","author":"A Takada","year":"1993","unstructured":"Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, et al. Contribution of carbohydrate antigens Sialyl Lewis A and Sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993;53:354\u201361.","journal-title":"Cancer Res"},{"key":"2417_CR79","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1023\/A:1011066308591\/METRICS","volume":"17","author":"KO Lloyd","year":"2000","unstructured":"Lloyd KO. The chemistry and immunochemistry of blood group A, B, H, and Lewis antigens: past, present and future. Glycoconj J. 2000;17:531\u201341. https:\/\/doi.org\/10.1023\/A:1011066308591\/METRICS","journal-title":"Glycoconj J"},{"key":"2417_CR80","doi-asserted-by":"publisher","first-page":"335649","DOI":"10.3389\/FONC.2018.00039\/BIBTEX","volume":"8","author":"A Blanas","year":"2018","unstructured":"Blanas A, Sahasrabudhe NM, Rodr\u00edguez E, van Kooyk Y, van Vliet SJ. Fucosylated antigens in cancer: an alliance toward tumor progression, metastasis, and resistance to chemotherapy. Front Oncol. 2018;8:335649. https:\/\/doi.org\/10.3389\/FONC.2018.00039\/BIBTEX","journal-title":"Front Oncol"},{"key":"2417_CR81","doi-asserted-by":"publisher","unstructured":"Trinchera M, Aronica A, Dall\u2019Olio F. Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers. Biology. 2017;6:16. https:\/\/doi.org\/10.3390\/BIOLOGY6010016","DOI":"10.3390\/BIOLOGY6010016"},{"key":"2417_CR82","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/SCIENCE.AAW3145\/SUPPL_FILE\/AAW3145_TABLE_S6.XLSX","volume":"364","author":"DD Engle","year":"2019","unstructured":"Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Sci (1979). 2019;364:1156\u201362. https:\/\/doi.org\/10.1126\/SCIENCE.AAW3145\/SUPPL_FILE\/AAW3145_TABLE_S6.XLSX","journal-title":"Sci (1979)"},{"key":"2417_CR83","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jcmgh.2015.12.003","volume":"2","author":"H Tang","year":"2016","unstructured":"Tang H, Partyka K, Hsueh P, Sinha JY, Kletter D, Zeh H, et al. Glycans related to the CA19-9 antigen are increased in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. CMGH. 2016;2:210\u2013e22115. https:\/\/doi.org\/10.1016\/j.jcmgh.2015.12.003","journal-title":"CMGH"},{"key":"2417_CR84","unstructured":"Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Glycosphingolipids 1999."},{"key":"2417_CR85","doi-asserted-by":"publisher","unstructured":"Russo D, Capolupo L, Loomba JS, Sticco L, D\u2019Angelo G. Glycosphingolipid metabolism in cell fate specification. J Cell Sci. 2018;131. https:\/\/doi.org\/10.1242\/JCS.219204\/77044","DOI":"10.1242\/JCS.219204\/77044"},{"key":"2417_CR86","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0962-8924(98)01249-5","volume":"8","author":"S Ichikawa","year":"1998","unstructured":"Ichikawa S, Hirabayashi Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol. 1998;8:198\u2013202. https:\/\/doi.org\/10.1016\/S0962-8924(98)01249-5","journal-title":"Trends Cell Biol"},{"key":"2417_CR87","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0304-4165(02)00410-5","volume":"1573","author":"J Marcus","year":"2002","unstructured":"Marcus J, Popko B. Galactolipids are molecular determinants of Myelin development and axo\u2013glial organization. Biochimica et biophysica acta (BBA) -. Gen Subj. 2002;1573:406\u201313. https:\/\/doi.org\/10.1016\/S0304-4165(02)00410-5","journal-title":"Gen Subj"},{"key":"2417_CR88","doi-asserted-by":"publisher","DOI":"10.1101\/GLYCOBIOLOGY.4E.11","author":"RL Schnaar","year":"2022","unstructured":"Schnaar RL, Sandhoff R, Tiemeyer M, Kinoshita T, Glycosphingolipids. Essentials Glycobiology. 2022. https:\/\/doi.org\/10.1101\/GLYCOBIOLOGY.4E.11","journal-title":"Essentials Glycobiology"},{"key":"2417_CR89","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/B978-044451967-2\/00092-1","volume":"4\u20134","author":"S Hakomori","year":"2007","unstructured":"Hakomori S, Structure, Functional Interaction of Glycosphingolipids Inducing Signal Transduction to Affect Cellular Phenotype. Compr Glycoscience: Chem Syst Biology. 2007;4\u20134:267\u201388. https:\/\/doi.org\/10.1016\/B978-044451967-2\/00092-1","journal-title":"Compr Glycoscience: Chem Syst Biology"},{"key":"2417_CR90","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/GLYCOB\/CWY026","volume":"28","author":"J Rybov\u00e1","year":"2018","unstructured":"Rybov\u00e1 J, Kucha\u0159 L, H\u016flkov\u00e1 H, Asfaw B, Dobrovoln\u00fd R, Sikora J, et al. Specific storage of glycoconjugates with terminal \u03b1-galactosyl moieties in the exocrine pancreas of Fabry disease patients with blood group B. Glycobiology. 2018;28:382\u201391. https:\/\/doi.org\/10.1093\/GLYCOB\/CWY026","journal-title":"Glycobiology"},{"key":"2417_CR91","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.1021\/ACS.ANALCHEM.0C00480\/SUPPL_FILE\/AC0C00480_SI_001.PDF","volume":"92","author":"T Bien","year":"2020","unstructured":"Bien T, Perl M, MacHm\u00fcller AC, Nitsche U, Conrad A, Johannes L, et al. MALDI-2 mass spectrometry and immunohistochemistry imaging of Gb3Cer, Gb4Cer, and further glycosphingolipids in human colorectal Cancer tissue. Anal Chem. 2020;92:7096\u2013105. https:\/\/doi.org\/10.1021\/ACS.ANALCHEM.0C00480\/SUPPL_FILE\/AC0C00480_SI_001.PDF","journal-title":"Anal Chem"},{"key":"2417_CR92","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1172\/JCI59735","volume":"122","author":"VL Battula","year":"2012","unstructured":"Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122:2066\u201378. https:\/\/doi.org\/10.1172\/JCI59735","journal-title":"J Clin Invest"},{"key":"2417_CR93","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1007\/S13361-017-1644-9\/SUPPL_FILE\/JS8B05604_SI_002.DOCX","volume":"28","author":"R Jir\u00e1sko","year":"2017","unstructured":"Jir\u00e1sko R, Hol\u010dapek M, Khalikova M, Vr\u00e1na D, \u0160tudent V, Prouzov\u00e1 Z, et al. MALDI orbitrap mass spectrometry profiling of dysregulated sulfoglycosphingolipids in renal cell carcinoma tissues. J Am Soc Mass Spectrom. 2017;28:1562\u201374. https:\/\/doi.org\/10.1007\/S13361-017-1644-9\/SUPPL_FILE\/JS8B05604_SI_002.DOCX","journal-title":"J Am Soc Mass Spectrom"},{"key":"2417_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55867-4","volume":"9","author":"N Sasaki","year":"2019","unstructured":"Sasaki N, Hirabayashi K, Michishita M, Takahashi K, Hasegawa F, Gomi F, et al. Ganglioside GM2, highly expressed in the MIA PaCa-2 pancreatic ductal adenocarcinoma cell line, is correlated with growth, invasion, and advanced stage. Sci Rep. 2019;9:1. https:\/\/doi.org\/10.1038\/s41598-019-55867-4","journal-title":"Sci Rep 2019"},{"key":"2417_CR95","doi-asserted-by":"publisher","unstructured":"Cumin C, Huang YL, Rossdam C, Ruoff F, C\u00e9spedes SP, Liang CY, et al. Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways. Cell Rep. 2022;40. https:\/\/doi.org\/10.1016\/J.CELREP.2022.111181\/ATTACHMENT\/93495B70-5005-48A8-B9E1-0241D3CE341D\/MMC1.PDF","DOI":"10.1016\/J.CELREP.2022.111181\/ATTACHMENT\/93495B70-5005-48A8-B9E1-0241D3CE341D\/MMC1.PDF"},{"key":"2417_CR96","doi-asserted-by":"publisher","first-page":"19087","DOI":"10.1073\/PNAS.0506474102\/SUPPL_FILE\/06474FIG8.JPG","volume":"102","author":"O Kovbasnjuk","year":"2005","unstructured":"Kovbasnjuk O, Mourtazina R, Baibakov B, Wang T, Elowsky C, Choti MA, et al. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci U S A. 2005;102:19087\u201392. https:\/\/doi.org\/10.1073\/PNAS.0506474102\/SUPPL_FILE\/06474FIG8.JPG","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-27765-9","volume":"13","author":"D Wolrab","year":"2022","unstructured":"Wolrab D, Jir\u00e1sko R, C\u00edfkov\u00e1 E, H\u00f6ring M, Mei D, Chocholou\u0161kov\u00e1 M, et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun. 2022;13:1. https:\/\/doi.org\/10.1038\/s41467-021-27765-9","journal-title":"Nat Commun 2022"},{"key":"2417_CR98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41419-022-05259-w","volume":"13","author":"YH Liu","year":"2022","unstructured":"Liu YH, Hu CM, Hsu YS, Lee WH. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma. Cell Death Disease. 2022;13:9. https:\/\/doi.org\/10.1038\/s41419-022-05259-w","journal-title":"Cell Death Disease 2022"},{"key":"2417_CR99","doi-asserted-by":"publisher","unstructured":"Heiden MGV, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science (1979) 2009;324:1029\u201333. https:\/\/doi.org\/10.1126\/SCIENCE.1160809","DOI":"10.1126\/SCIENCE.1160809"},{"key":"2417_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-36128-5","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, van der Hoeven R, Kattan WE, Chang JT, Montufar-Solis D, Chen W, et al. Glycolysis regulates KRAS plasma membrane localization and function through defined glycosphingolipids. Nat Commun. 2023;14:1. https:\/\/doi.org\/10.1038\/s41467-023-36128-5","journal-title":"Nat Commun 2023"},{"key":"2417_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-024-06087-8","volume":"7","author":"K Boelaars","year":"2024","unstructured":"Boelaars K, Rodriguez E, Huinen ZR, Liu C, Wang D, Springer BO, et al. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via Sialic acid-Siglec interactions. Commun Biology. 2024;7:1. https:\/\/doi.org\/10.1038\/s42003-024-06087-8","journal-title":"Commun Biology 2024"},{"key":"2417_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-020-01126-7","volume":"124","author":"C Dobie","year":"2020","unstructured":"Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer. 2020;124:1. https:\/\/doi.org\/10.1038\/s41416-020-01126-7","journal-title":"Br J Cancer 2020"},{"key":"2417_CR103","doi-asserted-by":"publisher","unstructured":"Bhalerao N, Chakraborty A, Marciel MP, Hwang J, Britain CM, Silva AD, et al. ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression. JCI Insight. 2023;8. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.161563","DOI":"10.1172\/JCI.INSIGHT.161563"},{"key":"2417_CR104","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2012.07.024","volume":"22","author":"CM Ardito","year":"2012","unstructured":"Ardito CM, Gr\u00fcner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, et al. EGF receptor is required for KRAS-Induced pancreatic tumorigenesis. Cancer Cell. 2012;22:304\u201317. https:\/\/doi.org\/10.1016\/j.ccr.2012.07.024","journal-title":"Cancer Cell"},{"key":"2417_CR105","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/GUTJNL-2016-312078","volume":"66","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, et al. Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124\u201336. https:\/\/doi.org\/10.1136\/GUTJNL-2016-312078","journal-title":"Gut"},{"key":"2417_CR106","doi-asserted-by":"publisher","first-page":"e007805","DOI":"10.1136\/JITC-2023-007805","volume":"11","author":"K Boelaars","year":"2023","unstructured":"Boelaars K, Goossens-Kruijssen L, Wang D, de Winde CM, Rodriguez E, Lindijer D, et al. Unraveling the impact of Sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer. J Immunother Cancer. 2023;11:e007805. https:\/\/doi.org\/10.1136\/JITC-2023-007805","journal-title":"J Immunother Cancer"},{"key":"2417_CR107","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/GLYCOB\/CWP115","volume":"19","author":"J Du","year":"2009","unstructured":"Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VDP, Yarema KJ. Metabolic glycoengineering: Sialic acid and beyond. Glycobiology. 2009;19:1382\u2013401. https:\/\/doi.org\/10.1093\/GLYCOB\/CWP115","journal-title":"Glycobiology"},{"key":"2417_CR108","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/nri2056","volume":"7","author":"PR Crocker","year":"2007","unstructured":"Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Reviews Immunol. 2007;7:4. https:\/\/doi.org\/10.1038\/nri2056","journal-title":"Nat Reviews Immunol 2007"},{"key":"2417_CR109","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/ANNUREV-IMMUNOL-102419-035900\/CITE\/REFWORKS","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365\u201395. https:\/\/doi.org\/10.1146\/ANNUREV-IMMUNOL-102419-035900\/CITE\/REFWORKS","journal-title":"Annu Rev Immunol"},{"key":"2417_CR110","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nri3737","volume":"14","author":"MS MacAuley","year":"2014","unstructured":"MacAuley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Reviews Immunol. 2014;14:10. https:\/\/doi.org\/10.1038\/nri3737","journal-title":"Nat Reviews Immunol 2014"},{"key":"2417_CR111","doi-asserted-by":"publisher","first-page":"e2026102118","DOI":"10.1073\/PNAS.2026102118\/SUPPL_FILE","volume":"118","author":"C B\u00fcll","year":"2021","unstructured":"B\u00fcll C, Nason R, Sun L, Van Coillie J, S\u00f8rensen DM, Moons SJ, et al. Probing the binding specificities of human Siglecs by cell-based glycan arrays. Proc Natl Acad Sci U S A. 2021;118:e2026102118. https:\/\/doi.org\/10.1073\/PNAS.2026102118\/SUPPL_FILE\/PNAS.2026102118.SAPP.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR112","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/GLYCOB\/CWI063","volume":"15","author":"A Harduin-Lepers","year":"2005","unstructured":"Harduin-Lepers A, Mollicone R, Delannoy P, Oriol R. The animal sialyltransferases and sialyltransferase-related genes: a phylogenetic approach. Glycobiology. 2005;15:805\u201317. https:\/\/doi.org\/10.1093\/GLYCOB\/CWI063","journal-title":"Glycobiology"},{"key":"2417_CR113","doi-asserted-by":"publisher","first-page":"18594","DOI":"10.1074\/jbc.M910204199","volume":"275","author":"K Angata","year":"2000","unstructured":"Angata K, Suzuki M, McAuliffe J, Ding Y, Hindsgaul O, Fukuda M. Differential biosynthesis of polysialic acid on neural cell adhesion molecule (NCAM) and oligosaccharide acceptors by three distinct \u03b12,8- sialyltransferases, ST8Sia IV (PST), ST8Sia II (STX), and ST8Sia III. J Biol Chem. 2000;275:18594\u2013601. https:\/\/doi.org\/10.1074\/jbc.M910204199","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"2417_CR114","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/J.1471-4159.2007.04716.X","volume":"103","author":"H Hildebrandt","year":"2007","unstructured":"Hildebrandt H, M\u00fchlenhoff M, Weinhold B, Gerardy-Schahn R. Dissecting polysialic acid and NCAM functions in brain development. J Neurochem. 2007;103(Suppl 1):56\u201364. https:\/\/doi.org\/10.1111\/J.1471-4159.2007.04716.X","journal-title":"J Neurochem"},{"key":"2417_CR115","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/J.BLRE.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28:143\u201353. https:\/\/doi.org\/10.1016\/J.BLRE.2014.04.001","journal-title":"Blood Rev"},{"key":"2417_CR116","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173:1439\u2013e145319. https:\/\/doi.org\/10.1016\/j.cell.2018.05.013","journal-title":"Cell"},{"key":"2417_CR117","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMOA1509277\/SUPPL_FILE","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353. https:\/\/doi.org\/10.1056\/NEJMOA1509277\/SUPPL_FILE\/NEJMOA1509277_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"key":"2417_CR118","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/CNCR.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA, L\u00f6wenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of Gemtuzumab Ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442\u201352. https:\/\/doi.org\/10.1002\/CNCR.21326","journal-title":"Cancer"},{"key":"2417_CR119","doi-asserted-by":"publisher","first-page":"101112","DOI":"10.1016\/J.MAM.2022.101112","volume":"90","author":"MA Stanczak","year":"2023","unstructured":"Stanczak MA, L\u00e4ubli H. Siglec receptors as new immune checkpoints in cancer. Mol Aspects Med. 2023;90:101112. https:\/\/doi.org\/10.1016\/J.MAM.2022.101112","journal-title":"Mol Aspects Med"},{"key":"2417_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-24366-4","volume":"12","author":"R Nason","year":"2021","unstructured":"Nason R, B\u00fcll C, Konstantinidi A, Sun L, Ye Z, Halim A, et al. Display of the human mucinome with defined O-glycans by gene engineered cells. Nat Commun. 2021;12:1. https:\/\/doi.org\/10.1038\/s41467-021-24366-4","journal-title":"Nat Commun 2021"},{"key":"2417_CR121","doi-asserted-by":"publisher","first-page":"10222","DOI":"10.1158\/0008-5472.CAN-06-2483","volume":"67","author":"BJ Swanson","year":"2007","unstructured":"Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA. MUC1 is a Counter-Receptor for Myelin-Associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic Cancer perineural invasion. Cancer Res. 2007;67:10222\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2483","journal-title":"Cancer Res"},{"key":"2417_CR122","doi-asserted-by":"publisher","first-page":"31842","DOI":"10.1074\/JBC.M113.471318","volume":"288","author":"S Tanida","year":"2013","unstructured":"Tanida S, Akita K, Ishida A, Mori Y, Toda M, Inoue M, et al. Binding of the Sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of \u03b2-catenin and subsequent cell growth. J Biol Chem. 2013;288:31842\u201352. https:\/\/doi.org\/10.1074\/JBC.M113.471318","journal-title":"J Biol Chem"},{"key":"2417_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-118\/FIGURES\/8","volume":"9","author":"JA Belisle","year":"2010","unstructured":"Belisle JA, Horibata S, Jennifer GAA, Petrie S, Kapur A, Andr\u00e9 S, et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer. 2010;9:1\u201314. https:\/\/doi.org\/10.1186\/1476-4598-9-118\/FIGURES\/8","journal-title":"Mol Cancer"},{"key":"2417_CR124","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/J.BBRC.2010.10.079","volume":"402","author":"M Ohta","year":"2010","unstructured":"Ohta M, Ishida A, Toda M, Akita K, Inoue M, Yamashita K, et al. Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem Biophys Res Commun. 2010;402:663\u20139. https:\/\/doi.org\/10.1016\/J.BBRC.2010.10.079","journal-title":"Biochem Biophys Res Commun"},{"key":"2417_CR125","doi-asserted-by":"publisher","first-page":"e2107424118","DOI":"10.1073\/PNAS.2107424118\/SUPPL_FILE","volume":"118","author":"I Ibarlucea-Benitez","year":"2021","unstructured":"Ibarlucea-Benitez I, Weitzenfeld P, Smith P, Ravetch JV. Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2021;118:e2107424118. https:\/\/doi.org\/10.1073\/PNAS.2107424118\/SUPPL_FILE\/PNAS.2107424118.SAPP.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR126","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/GLYCOB\/CWQ085","volume":"20","author":"G Picco","year":"2010","unstructured":"Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology. 2010;20:1241\u201350. https:\/\/doi.org\/10.1093\/GLYCOB\/CWQ085","journal-title":"Glycobiology"},{"key":"2417_CR127","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3892\/IJO.25.4.937","volume":"25","author":"A Mungul","year":"2004","unstructured":"Mungul A, Cooper L, Brockhausen I, Ryder K, Mandel U, Clausen H, et al. Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 Transgenic mice. Int J Oncol. 2004;25:937\u201380. https:\/\/doi.org\/10.3892\/IJO.25.4.937","journal-title":"Int J Oncol"},{"key":"2417_CR128","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/ni.3552","volume":"17","author":"R Beatson","year":"2016","unstructured":"Beatson R, Tajadura-Ortega V, Achkova D, Picco G, Tsourouktsoglou TD, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:11. https:\/\/doi.org\/10.1038\/ni.3552","journal-title":"Nat Immunol 2016"},{"key":"2417_CR129","doi-asserted-by":"publisher","unstructured":"Beatson R, Graham R, Grundland Freile F, Cozzetto D, Kannambath S, Pfeifer E, et al. Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype. Commun Biol. 2020;3. https:\/\/doi.org\/10.1038\/S42003-020-01359-5","DOI":"10.1038\/S42003-020-01359-5"},{"key":"2417_CR130","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","volume":"124","author":"C Jandus","year":"2014","unstructured":"Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, D\u00e9moulins T, et al. Interactions between Siglec-7\/9 receptors and ligands influence NK cell\u2013dependent tumor immunosurveillance. J Clin Invest. 2014;124:1810\u201320. https:\/\/doi.org\/10.1172\/JCI65899","journal-title":"J Clin Invest"},{"key":"2417_CR131","doi-asserted-by":"publisher","first-page":"13787","DOI":"10.1073\/PNAS.1203339109\/SUPPL_FILE\/PNAS.201203339SI.PDF","volume":"109","author":"NV Chaika","year":"2012","unstructured":"Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A. 2012;109:13787\u201392. https:\/\/doi.org\/10.1073\/PNAS.1203339109\/SUPPL_FILE\/PNAS.201203339SI.PDF","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR132","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","volume":"32","author":"SK Shukla","year":"2017","unstructured":"Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic Cancer. Cancer Cell. 2017;32:71\u2013e877. https:\/\/doi.org\/10.1016\/j.ccell.2017.06.004","journal-title":"Cancer Cell"},{"key":"2417_CR133","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1158\/0008-5472.CAN-10-4439\/649735\/AM\/PANCREATIC-DUCTAL-ADENOCARCINOMA-PDA-MICE-LACKING","volume":"71","author":"DM Besmer","year":"2011","unstructured":"Besmer DM, Curry JM, Roy LD, Tinder TL, Sahraei M, Schettini J, et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res. 2011;71:4432\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4439\/649735\/AM\/PANCREATIC-DUCTAL-ADENOCARCINOMA-PDA-MICE-LACKING.","journal-title":"Cancer Res"},{"key":"2417_CR134","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/GLYCOB\/CWL061","volume":"17","author":"MA Tarp","year":"2007","unstructured":"Tarp MA, S\u00f8rensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology. 2007;17:197\u2013209. https:\/\/doi.org\/10.1093\/GLYCOB\/CWL061","journal-title":"Glycobiology"},{"key":"2417_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emm.2017.231","volume":"50","author":"SJ Jeong","year":"2018","unstructured":"Jeong SJ, Kim JH, Lim BJ, Yoon I, Song JA, Moon HS, et al. Inhibition of MUC1 biosynthesis via threonyl-tRNA synthetase suppresses pancreatic cancer cell migration. Experimental Mol Med. 2018;50:1. https:\/\/doi.org\/10.1038\/emm.2017.231","journal-title":"Experimental Mol Med 2018"},{"key":"2417_CR136","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"AD Posey","year":"2016","unstructured":"Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, et al. Engineered CAR T cells targeting the Cancer-Associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44:1444\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.014","journal-title":"Immunity"},{"key":"2417_CR137","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1158\/1541-7786.MCR-21-0888\/696482","volume":"20","author":"S Marimuthu","year":"2022","unstructured":"Marimuthu S, Lakshmanan I, Muniyan S, Gautam SK, Nimmakayala RK, Rauth S, et al. MUC16 promotes liver metastasis of pancreatic ductal adenocarcinoma by upregulating NRP2-Associated cell adhesion. Mol Cancer Res. 2022;20:1208\u201321. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0888\/696482\/AM\/MUC16-PROMOTES-LIVER-METASTASIS-OF-PANCREATIC.","journal-title":"Mol Cancer Res"},{"key":"2417_CR138","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41388-022-02493-6","volume":"41","author":"I Lakshmanan","year":"2022","unstructured":"Lakshmanan I, Marimuthu S, Chaudhary S, Seshacharyulu P, Rachagani S, Muniyan S, et al. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Oncogene. 2022;41:48. https:\/\/doi.org\/10.1038\/s41388-022-02493-6","journal-title":"Oncogene 2022"},{"key":"2417_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18907-6","volume":"11","author":"E Rodrigues","year":"2020","unstructured":"Rodrigues E, Jung J, Park H, Loo C, Soukhtehzari S, Kitova EN, et al. A versatile soluble Siglec scaffold for sensitive and quantitative detection of glycan ligands. Nat Commun. 2020;11:1. https:\/\/doi.org\/10.1038\/s41467-020-18907-6","journal-title":"Nat Commun 2020"},{"key":"2417_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21550-4","volume":"12","author":"E Rodriguez","year":"2021","unstructured":"Rodriguez E, Boelaars K, Brown K, Eveline Li RJ, Kruijssen L, Bruijns SCM, et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat Commun. 2021;12:1. https:\/\/doi.org\/10.1038\/s41467-021-21550-4","journal-title":"Nat Commun 2021"},{"key":"2417_CR141","doi-asserted-by":"publisher","first-page":"105579","DOI":"10.1016\/j.jbc.2023.105579","volume":"300","author":"N Stewart","year":"2024","unstructured":"Stewart N, Daly J, Drummond-Guy O, Krishnamoorthy V, Stark JC, Riley NM, et al. The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation. J Biol Chem. 2024;300:105579. https:\/\/doi.org\/10.1016\/j.jbc.2023.105579","journal-title":"J Biol Chem"},{"key":"2417_CR142","doi-asserted-by":"publisher","first-page":"e2215376120","DOI":"10.1073\/PNAS.2215376120\/SUPPL_FILE\/PNAS.2215376120.SD06.XLSX","volume":"120","author":"BAH Smith","year":"2023","unstructured":"Smith BAH, Deutzmann A, Correa KM, Delaveris CS, Dhanasekaran R, Dove CG, et al. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint. Proc Natl Acad Sci U S A. 2023;120:e2215376120. https:\/\/doi.org\/10.1073\/PNAS.2215376120\/SUPPL_FILE\/PNAS.2215376120.SD06.XLSX","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR143","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1172\/JCI120612","volume":"128","author":"MA Stanczak","year":"2018","unstructured":"Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, Von Gunten S, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018;128:4912\u201323. https:\/\/doi.org\/10.1172\/JCI120612","journal-title":"J Clin Invest"},{"key":"2417_CR144","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-18-0505\/470929\/","volume":"7","author":"Q Haas","year":"2019","unstructured":"Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, et al. Siglec-9 regulates an effector memory CD8\u00fe T-cell subset that congregates in the melanoma tumor microenvironment. Cancer Immunol Res. 2019;7:707\u201318. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0505\/470929\/AM\/SIGLEC-9-REGULATES-AN-EFFECTOR-MEMORY-CD8-T-CELL.","journal-title":"Cancer Immunol Res"},{"key":"2417_CR145","doi-asserted-by":"publisher","first-page":"112475","DOI":"10.1016\/j.celrep.2023.112475","volume":"42","author":"H Egan","year":"2023","unstructured":"Egan H, Treacy O, Lynch K, Leonard NA, O\u2019Malley G, Reidy E, et al. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment. Cell Rep. 2023;42:112475. https:\/\/doi.org\/10.1016\/j.celrep.2023.112475","journal-title":"Cell Rep"},{"key":"2417_CR146","doi-asserted-by":"publisher","unstructured":"Stanczak MA, Mantuano NR, Kirchhammer N, Sanin DE, Jacob F, Coelho R et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint Blockade. Sci Transl Med 2022;14. https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABJ1270\/SUPPL_FILE\/SCITRANSLMED.ABJ1270_MDAR_REPRODUCIBILITY_CHECKLIST.PDF","DOI":"10.1126\/SCITRANSLMED.ABJ1270\/SUPPL_FILE\/SCITRANSLMED.ABJ1270_MDAR_REPRODUCIBILITY_CHECKLIST.PDF"},{"key":"2417_CR147","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41417-023-00713-z","volume":"31","author":"Z Huang","year":"2023","unstructured":"Huang Z, Guo Y, Li B, Shen M, Yi Y, Li L, et al. Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma. Cancer Gene Therapy 2023. 2023;31:3. https:\/\/doi.org\/10.1038\/s41417-023-00713-z","journal-title":"Cancer Gene Therapy 2023"},{"key":"2417_CR148","doi-asserted-by":"publisher","first-page":"TPS3166","DOI":"10.1200\/JCO.2020.38.15_SUPPL.TPS3166","volume":"38","author":"M Gutierrez","year":"2020","unstructured":"Gutierrez M, Hamid O, Shum E, Wise DR, Balar AV, Weber JS, et al. Trial in progress: A phase I\/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors. J Clin Oncol. 2020;38:TPS3166\u20133166. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_SUPPL.TPS3166","journal-title":"J Clin Oncol"},{"key":"2417_CR149","unstructured":"Study Details| Glycan Mediated Immune Regulation. With a Bi-Sialidase Fusion Protein (GLIMMER-01)| ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT05259696 (accessed June 17, 2025)."},{"key":"2417_CR150","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.CYTOGFR.2012.09.003","volume":"24","author":"D Walsh","year":"2013","unstructured":"Walsh D, McCarthy J, O\u2019Driscoll C, Melgar S. Pattern recognition receptors\u2014Molecular orchestrators of inflammation in inflammatory bowel disease. Cytokine Growth Factor Rev. 2013;24:91\u2013104. https:\/\/doi.org\/10.1016\/J.CYTOGFR.2012.09.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"2417_CR151","doi-asserted-by":"publisher","first-page":"417707","DOI":"10.3389\/FIMMU.2018.02379\/BIBTEX","volume":"9","author":"GP Amarante-Mendes","year":"2018","unstructured":"Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:417707. https:\/\/doi.org\/10.3389\/FIMMU.2018.02379\/BIBTEX","journal-title":"Front Immunol"},{"key":"2417_CR152","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/J.1600-065X.1998.TB01185.X","volume":"163","author":"WI Weis","year":"1998","unstructured":"Weis WI, Taylor ME, Drickamer K, Weis\u2019 WI, Taylor- ME, Dridmraer\u2019 K, et al. The C-type lectin superfamily in the immune system. Immunol Rev. 1998;163:19\u201334. https:\/\/doi.org\/10.1111\/J.1600-065X.1998.TB01185.X","journal-title":"Immunol Rev"},{"key":"2417_CR153","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/ni.f.203","volume":"9","author":"Y van Kooyk","year":"2008","unstructured":"van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008. 2008;9:6. https:\/\/doi.org\/10.1038\/ni.f.203","journal-title":"Nat Immunol 2008"},{"key":"2417_CR154","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/GLYCOB\/CWQ193","volume":"21","author":"RT Lee","year":"2011","unstructured":"Lee RT, Hsu TL, Huang SK, Hsieh SL, Wong CH, Lee YC. Survey of immune-related, mannose\/fucose-binding C-type lectin receptors reveals widely divergent sugar-binding specificities. Glycobiology. 2011;21:512\u201320. https:\/\/doi.org\/10.1093\/GLYCOB\/CWQ193","journal-title":"Glycobiology"},{"key":"2417_CR155","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nri2569","volume":"9","author":"TBH Geijtenbeek","year":"2009","unstructured":"Geijtenbeek TBH, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Reviews Immunol 2009. 2009;9:7. https:\/\/doi.org\/10.1038\/nri2569","journal-title":"Nat Reviews Immunol 2009"},{"key":"2417_CR156","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/J.CEB.2007.09.004","volume":"19","author":"ME Taylor","year":"2007","unstructured":"Taylor ME, Drickamer K. Paradigms for glycan-binding receptors in cell adhesion. Curr Opin Cell Biol. 2007;19:572\u20137. https:\/\/doi.org\/10.1016\/J.CEB.2007.09.004","journal-title":"Curr Opin Cell Biol"},{"key":"2417_CR157","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri1182","volume":"3","author":"Y Van Kooyk","year":"2003","unstructured":"Van Kooyk Y, Geijtenbeek TBH. DC-SIGN: escape mechanism for pathogens. Nat Reviews Immunol. 2003;3:9. https:\/\/doi.org\/10.1038\/nri1182","journal-title":"Nat Reviews Immunol 2003"},{"key":"2417_CR158","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/J.IMMUNI.2015.05.021","volume":"42","author":"JJ Garcia-Vallejo","year":"2015","unstructured":"Garcia-Vallejo JJ, van Kooyk Y. DC-SIGN: the strange case of dr. Jekyll and Mr. Hyde Immun. 2015;42:983\u20135. https:\/\/doi.org\/10.1016\/J.IMMUNI.2015.05.021","journal-title":"Hyde Immun"},{"key":"2417_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12964-023-01388-7\/FIGURES\/5","volume":"22","author":"Z Hussain","year":"2024","unstructured":"Hussain Z, Bertran T, Finetti P, Lohmann E, Mamessier E, Bidaut G, et al. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer. Cell Communication Signal. 2024;22:1\u201317. https:\/\/doi.org\/10.1186\/S12964-023-01388-7\/FIGURES\/5","journal-title":"Cell Communication Signal"},{"key":"2417_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-40895-6","volume":"14","author":"K Oh","year":"2023","unstructured":"Oh K, Yoo YJ, Torre-Healy LA, Rao M, Fassler D, Wang P, et al. Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype. Nat Commun. 2023;14:1. https:\/\/doi.org\/10.1038\/s41467-023-40895-6","journal-title":"Nat Commun 2023"},{"key":"2417_CR161","doi-asserted-by":"publisher","first-page":"8358","DOI":"10.1158\/0008-5472.CAN-07-1035","volume":"67","author":"C Napoletano","year":"2007","unstructured":"Napoletano C, Rughetti A, Agervig Tarp MP, Coleman J, Bennett EP, Picco G, et al. Tumor-Associated Tn-MUC1 glycoform is internalized through the macrophage Galactose-Type C-Type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res. 2007;67:8358\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1035","journal-title":"Cancer Res"},{"key":"2417_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrc1251","volume":"4","author":"MA Hollingsworth","year":"2004","unstructured":"Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Reviews Cancer. 2004;4:1. https:\/\/doi.org\/10.1038\/nrc1251","journal-title":"Nat Reviews Cancer 2004"},{"key":"2417_CR163","doi-asserted-by":"publisher","first-page":"10279","DOI":"10.1111\/JCMM.15684","volume":"24","author":"S Wang","year":"2020","unstructured":"Wang S, You L, Dai M, Zhao Y. Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy. J Cell Mol Med. 2020;24:10279\u201389. https:\/\/doi.org\/10.1111\/JCMM.15684","journal-title":"J Cell Mol Med"},{"key":"2417_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FONC.2021.670396\/FULL","volume":"11","author":"JK Striefler","year":"2021","unstructured":"Striefler JK, Riess H, Lohneis P, Bischoff S, Kurreck A, Modest DP, et al. Mucin-1 protein is a prognostic marker for pancreatic ductal adenocarcinoma: results from the CONKO-001 study. Front Oncol. 2021;11:1. https:\/\/doi.org\/10.3389\/FONC.2021.670396\/FULL","journal-title":"Front Oncol"},{"key":"2417_CR165","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876\/712817\/","volume":"13","author":"C Falcomat\u00e0","year":"2023","unstructured":"Falcomat\u00e0 C, B\u00e4rthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D. Context-Specific determinants of the immunosuppressive tumor microenvironment in pancreatic Cancer. Cancer Discov. 2023;13:278\u201397. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0876\/712817\/P\/CONTEXT-SPECIFIC-DETERMINANTS-OF-THE.","journal-title":"Cancer Discov"},{"key":"2417_CR166","unstructured":"Study Details.| A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers| ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT04025216 (accessed April 1, 2024)."},{"key":"2417_CR167","doi-asserted-by":"publisher","unstructured":"Gutierrez R, Shah PD, Hamid O, Garfall AL, Posey A, Bishop MR et al. Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. 2021;39:e14513\u201314513. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_SUPPL.E14513","DOI":"10.1200\/JCO.2021.39.15_SUPPL.E14513"},{"key":"2417_CR168","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:4. https:\/\/doi.org\/10.1038\/nm.2344","journal-title":"Nat Med 2011"},{"key":"2417_CR169","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:10. https:\/\/doi.org\/10.1038\/ng.3398","journal-title":"Nat Genet 2015"},{"key":"2417_CR170","doi-asserted-by":"publisher","first-page":"7592","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nat. 2016;531:7592. https:\/\/doi.org\/10.1038\/nature16965","journal-title":"Nat 2016"},{"key":"2417_CR171","doi-asserted-by":"publisher","first-page":"E3769","DOI":"10.1073\/PNAS.1722434115\/SUPPL_FILE\/PNAS.1722434115.SD01.XLS","volume":"115","author":"CA Orozco","year":"2018","unstructured":"Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor\u2013stroma crosstalk. Proc Natl Acad Sci U S A. 2018;115:E3769\u201378. https:\/\/doi.org\/10.1073\/PNAS.1722434115\/SUPPL_FILE\/PNAS.1722434115.SD01.XLS","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12974-019-1522-4\/FIGURES\/6","volume":"16","author":"JM Ilarregui","year":"2019","unstructured":"Ilarregui JM, Kooij G, Rodr\u00edguez E, Van Der Pol SMA, Koning N, Kalay H, et al. Macrophage galactose-type lectin (MGL) is induced on M2 microglia and participates in the resolution phase of autoimmune neuroinflammation. J Neuroinflammation. 2019;16:1\u201314. https:\/\/doi.org\/10.1186\/S12974-019-1522-4\/FIGURES\/6","journal-title":"J Neuroinflammation"},{"key":"2417_CR173","doi-asserted-by":"publisher","first-page":"8385","DOI":"10.1073\/PNAS.1500956112\/SUPPL_FILE\/PNAS.201500956SI.PDF","volume":"112","author":"N Cox","year":"2015","unstructured":"Cox N, Pilling D, Gomer RH, Ravetch JV. DC-SIGN activation mediates the differential effects of SAP and CRP on the innate immune system and inhibits fibrosis in mice. Proc Natl Acad Sci U S A. 2015;112:8385\u201390. https:\/\/doi.org\/10.1073\/PNAS.1500956112\/SUPPL_FILE\/PNAS.201500956SI.PDF","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR174","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1158\/0008-5472.CAN-16-2212\/652658\/","volume":"77","author":"JA Kenkel","year":"2017","unstructured":"Kenkel JA, Tseng WW, Davidson MG, Tolentino LL, Choi O, Bhattacharya N, et al. An immunosuppressive dendritic cell subset accumulates at secondary sites and promotes metastasis in pancreatic cancer. Cancer Res. 2017;77:4158\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2212\/652658\/AM\/AN-IMMUNOSUPPRESSIVE-DENDRITIC-CELL-SUBSET.","journal-title":"Cancer Res"},{"key":"2417_CR175","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/NI1408","volume":"8","author":"PR Taylor","year":"2007","unstructured":"Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007;8:31\u20138. https:\/\/doi.org\/10.1038\/NI1408","journal-title":"Nat Immunol"},{"key":"2417_CR176","doi-asserted-by":"publisher","first-page":"812148","DOI":"10.3389\/FIMMU.2022.812148","volume":"13","author":"P Mata-Mart\u00ednez","year":"2022","unstructured":"Mata-Mart\u00ednez P, Berg\u00f3n-Guti\u00e9rrez M, del Fresno C. Dectin-1 signaling update: new perspectives for trained immunity. Front Immunol. 2022;13:812148. https:\/\/doi.org\/10.3389\/FIMMU.2022.812148","journal-title":"Front Immunol"},{"key":"2417_CR177","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.celrep.2015.10.058","volume":"13","author":"L Seifert","year":"2015","unstructured":"Seifert L, Deutsch M, Alothman S, Alqunaibit D, Werba G, Pansari M, et al. Dectin-1 regulates hepatic fibrosis and hepatocarcinogenesis by suppressing TLR4 signaling pathways. Cell Rep. 2015;13:1909\u201321. https:\/\/doi.org\/10.1016\/j.celrep.2015.10.058","journal-title":"Cell Rep"},{"key":"2417_CR178","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nm.4314","volume":"23","author":"D Daley","year":"2017","unstructured":"Daley D, Mani VR, Mohan N, Akkad N, Ochi A, Heindel DW, et al. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat Med 2017. 2017;23:5. https:\/\/doi.org\/10.1038\/nm.4314","journal-title":"Nat Med 2017"},{"key":"2417_CR179","doi-asserted-by":"publisher","unstructured":"Wattenberg MM, Coho H, Herrera VM, Graham K, Stone ML, Xue Y et al. Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Sci Immunol 2023;8. https:\/\/doi.org\/10.1126\/SCIIMMUNOL.ADJ5097\/SUPPL_FILE\/SCIIMMUNOL.ADJ5097_MDAR_REPRODUCIBILITY_CHECKLIST.PDF","DOI":"10.1126\/SCIIMMUNOL.ADJ5097\/SUPPL_FILE\/SCIIMMUNOL.ADJ5097_MDAR_REPRODUCIBILITY_CHECKLIST.PDF"},{"key":"2417_CR180","unstructured":"A Maintenance Therapy. Study of Odetiglucan With a CD40 Agonist (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma - Full Text View - ClinicalTrials.gov n.d. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05484011 (accessed April 6, 2024)."},{"key":"2417_CR181","doi-asserted-by":"publisher","first-page":"102394","DOI":"10.1016\/J.SBI.2022.102394","volume":"75","author":"RD Cummings","year":"2022","unstructured":"Cummings RD. The mannose receptor ligands and the macrophage glycome. Curr Opin Struct Biol. 2022;75:102394. https:\/\/doi.org\/10.1016\/J.SBI.2022.102394","journal-title":"Curr Opin Struct Biol"},{"key":"2417_CR182","doi-asserted-by":"publisher","first-page":"100368","DOI":"10.1016\/j.jbc.2021.100368","volume":"296","author":"H Feinberg","year":"2021","unstructured":"Feinberg H, J\u00e9gouzo SAF, Lasanajak Y, Smith DF, Drickamer K, Weis WI, et al. Structural analysis of carbohydrate binding by the macrophage mannose receptor CD206. J Biol Chem. 2021;296:100368. https:\/\/doi.org\/10.1016\/j.jbc.2021.100368","journal-title":"J Biol Chem"},{"key":"2417_CR183","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0021-9258(18)54164-8","volume":"268","author":"ME Taylor","year":"1993","unstructured":"Taylor ME, Drickamer K. Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor. J Biol Chem. 1993;268:399\u2013404. https:\/\/doi.org\/10.1016\/S0021-9258(18)54164-8","journal-title":"J Biol Chem"},{"key":"2417_CR184","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41419-018-0486-0","volume":"9","author":"H Ye","year":"2018","unstructured":"Ye H, Zhou Q, Zheng S, Li G, Lin Q, Wei L, et al. Tumor-associated macrophages promote progression and the Warburg effect via CCL18\/NF-kB\/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Cell Death Disease. 2018;9:5. https:\/\/doi.org\/10.1038\/s41419-018-0486-0","journal-title":"Cell Death Disease 2018"},{"key":"2417_CR185","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.immuni.2017.07.014","volume":"47","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, et al. Tissue-Resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity. 2017;47:323\u2013e3386. https:\/\/doi.org\/10.1016\/j.immuni.2017.07.014","journal-title":"Immunity"},{"key":"2417_CR186","doi-asserted-by":"publisher","unstructured":"Stavenhagen K, Mehta AY, Laan L, Gao C, Heimburg-Molinaro J, van Die I et al. N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains. J Biol Chem 2022;298. https:\/\/doi.org\/10.1016\/j.jbc.2022.102591","DOI":"10.1016\/j.jbc.2022.102591"},{"key":"2417_CR187","doi-asserted-by":"publisher","unstructured":"Morimoto M, Till NA, Bertozzi CR. Tumor Immune Cell Targeting Chimeras (TICTACs) For Targeted Depletion of Macrophage-Associated Checkpoint Receptors. BioRxiv 2023;2023.12.06.570444. https:\/\/doi.org\/10.1101\/2023.12.06.570444","DOI":"10.1101\/2023.12.06.570444"},{"key":"2417_CR188","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1101\/GLYCOBIOLOGY.4E.36","volume":"4\u20134","author":"RD Cummings","year":"2022","unstructured":"Cummings RD, Liu F-T, Rabinovich GA, Stowell SR, Vasta GR, Galectins. Carbohydrates Chem Biology. 2022;4\u20134:625\u201347. https:\/\/doi.org\/10.1101\/GLYCOBIOLOGY.4E.36","journal-title":"Carbohydrates Chem Biology"},{"key":"2417_CR189","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3978\/J.ISSN.2305-5839.2014.09.12","volume":"2","author":"AH Ebrahim","year":"2014","unstructured":"Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda R, Dahlbeck S, Nguyen D, et al. Galectins in cancer: carcinogenesis, diagnosis and therapy. Ann Transl Med. 2014;2:88\u201388. https:\/\/doi.org\/10.3978\/J.ISSN.2305-5839.2014.09.12","journal-title":"Ann Transl Med"},{"key":"2417_CR190","doi-asserted-by":"publisher","unstructured":"Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nature Reviews Cancer. 2005;5(1):29\u201341. https:\/\/doi.org\/10.1038\/nrc1527","DOI":"10.1038\/nrc1527"},{"key":"2417_CR191","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1074\/jbc.M409752200","volume":"280","author":"P Matarrese","year":"2005","unstructured":"Matarrese P, Tinari A, Mormone E, Bianco GA, Toscano MA, Ascione B, et al. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem. 2005;280:6969\u201385. https:\/\/doi.org\/10.1074\/jbc.M409752200","journal-title":"J Biol Chem"},{"key":"2417_CR192","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1074\/jbc.M412019200","volume":"280","author":"A Lepp\u00e4nen","year":"2005","unstructured":"Lepp\u00e4nen A, Stowell S, Blixt O, Cummings RD. Dimeric galectin-1 binds with high affinity to \u03b12,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J Biol Chem. 2005;280:5549\u201362. https:\/\/doi.org\/10.1074\/jbc.M412019200","journal-title":"J Biol Chem"},{"key":"2417_CR193","doi-asserted-by":"publisher","first-page":"e952201","DOI":"10.4161\/21624011.2014.952201","volume":"3","author":"N Mart\u00ednez-Bosch","year":"2014","unstructured":"Mart\u00ednez-Bosch N, Navarro P. Targeting Galectin-1 in pancreatic cancer: immune surveillance on guard. Oncoimmunology. 2014;3:e952201. https:\/\/doi.org\/10.4161\/21624011.2014.952201","journal-title":"Oncoimmunology"},{"key":"2417_CR194","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1007\/S13277-015-3233-5\/METRICS","volume":"36","author":"D Tang","year":"2015","unstructured":"Tang D, Gao J, Wang S, Yuan Z, Ye N, Chong Y, et al. Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. Tumor Biology. 2015;36:5617\u201326. https:\/\/doi.org\/10.1007\/S13277-015-3233-5\/METRICS","journal-title":"Tumor Biology"},{"key":"2417_CR195","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1038\/378736a0","volume":"378","author":"NL Perillo","year":"1995","unstructured":"Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nat. 1995;378:6558. https:\/\/doi.org\/10.1038\/378736a0","journal-title":"Nat 1995"},{"key":"2417_CR196","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.4049\/JIMMUNOL.165.5.2331","volume":"165","author":"KE Pace","year":"2000","unstructured":"Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. Cutting edge: CD7 delivers a Pro-Apoptotic signal during Galectin-1-Induced T cell death. J Immunol. 2000;165:2331\u20134. https:\/\/doi.org\/10.4049\/JIMMUNOL.165.5.2331","journal-title":"J Immunol"},{"key":"2417_CR197","doi-asserted-by":"publisher","unstructured":"Bogut A, Stojanovic B, Jovanovic M, Dimitrijevic Stojanovic M, Gajovic N, Stojanovic BS, et al. Galectin-1 in pancreatic ductal adenocarcinoma: bridging tumor biology, immune evasion, and therapeutic opportunities. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/IJMS242115500","DOI":"10.3390\/IJMS242115500"},{"key":"2417_CR198","doi-asserted-by":"publisher","first-page":"14496","DOI":"10.1073\/PNAS.0903497106\/SUPPL_FILE\/0903497106SI.PDF","volume":"106","author":"HY Chen","year":"2009","unstructured":"Chen HY, Fermin A, Vardhana S, Weng IC, Lo KFR, Chang EY, et al. Galectin-3 negatively regulates TCR-mediated CD4\u2009+\u2009T-cell activation at the immunological synapse. Proc Natl Acad Sci U S A. 2009;106:14496\u2013501. https:\/\/doi.org\/10.1073\/PNAS.0903497106\/SUPPL_FILE\/0903497106SI.PDF","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR199","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150\/470258\/","volume":"3","author":"T Kouo","year":"2015","unstructured":"Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8 T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015;3:412\u201323. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0150\/470258\/AM\/GALECTIN-3-SHAPES-ANTI-TUMOR-IMMUNE-RESPONSES-BY.","journal-title":"Cancer Immunol Res"},{"key":"2417_CR200","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/J.CCR.2005.04.023\/ATTACHMENT\/5A08165E-7F4C-4E88-AA1D-384C993E274E\/MMC1.PDF","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469\u201383. https:\/\/doi.org\/10.1016\/J.CCR.2005.04.023\/ATTACHMENT\/5A08165E-7F4C-4E88-AA1D-384C993E274E\/MMC1.PDF","journal-title":"Cancer Cell"},{"key":"2417_CR201","doi-asserted-by":"publisher","unstructured":"Yang D, Sun X, Moniruzzaman R, Wang H, Citu C, Zhao Z, et al. Genetic deletion of Galectin-3 inhibits pancreatic Cancer progression and enhances the efficacy of immunotherapy. Gastroenterology. 2024;0. https:\/\/doi.org\/10.1053\/j.gastro.2024.03.007","DOI":"10.1053\/j.gastro.2024.03.007"},{"key":"2417_CR202","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2326-6066.CIR-21-1088\/711503\/","volume":"11","author":"T Lidstr\u00f6m","year":"2023","unstructured":"Lidstr\u00f6m T, Cumming J, Gaur R, Fr\u00e4ngsmyr L, Pateras IS, Mickert MJ, et al. Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic Cancer. Cancer Immunol Res. 2023;11:72\u201392. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-1088\/711503\/AM\/EXTRACELLULAR-GALECTIN-4-DRIVES-IMMUNE-EVASION-AND.","journal-title":"Cancer Immunol Res"},{"key":"2417_CR203","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41388-020-1186-7","volume":"39","author":"AM Seifert","year":"2020","unstructured":"Seifert AM, Reiche C, Heiduk M, Tannert A, Meinecke AC, Baier S, et al. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Oncogene. 2020;39:15. https:\/\/doi.org\/10.1038\/s41388-020-1186-7","journal-title":"Oncogene 2020"},{"key":"2417_CR204","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/J.1365-2567.2003.01738.X","volume":"110","author":"EW Hewitt","year":"2003","unstructured":"Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 2003;110:163\u20139. https:\/\/doi.org\/10.1046\/J.1365-2567.2003.01738.X","journal-title":"Immunology"},{"key":"2417_CR205","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0022-2836(91)90567-P","volume":"219","author":"MA Saper","year":"1991","unstructured":"Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 \u00c5 resolution. J Mol Biol. 1991;219:277\u2013319. https:\/\/doi.org\/10.1016\/0022-2836(91)90567-P","journal-title":"J Mol Biol"},{"key":"2417_CR206","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1038\/329506a0","volume":"329","author":"PJ Bjorkman","year":"1987","unstructured":"Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nat. 1987;329:6139. https:\/\/doi.org\/10.1038\/329506a0","journal-title":"Nat 1987"},{"key":"2417_CR207","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/EJI.1830190319","volume":"19","author":"CJP Boog","year":"1989","unstructured":"Boog CJP, Neefjes JJ, Boes J, Ploegh HL, Melief CJM. Specific immune responses restored by alteration in carbohydrate chains of surface molecules on antigen-presenting cells. Eur J Immunol. 1989;19:537\u201342. https:\/\/doi.org\/10.1002\/EJI.1830190319","journal-title":"Eur J Immunol"},{"key":"2417_CR208","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1002\/J.1460-2075.1988.TB03208.X","volume":"7","author":"JG Bolscher","year":"1988","unstructured":"Bolscher JG, van der Bijl MM, Neefjes JJ, Hall A, Smets LA, Ploegh HL. Ras (proto)oncogene induces N-linked carbohydrate modification: Temporal relationship with induction of invasive potential. EMBO J. 1988;7:3361\u20138. https:\/\/doi.org\/10.1002\/J.1460-2075.1988.TB03208.X","journal-title":"EMBO J"},{"key":"2417_CR209","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/J.IMMUNI.2020.11.003\/ATTACHMENT\/270C03F8-3202-49CD-9524-908915DF54A8\/MMC1.PDF","volume":"54","author":"MLM Jongsma","year":"2021","unstructured":"Jongsma MLM, de Waard AA, Raaben M, Zhang T, Cabukusta B, Platzer R, et al. The SPPL3-Defined glycosphingolipid repertoire orchestrates HLA class I-Mediated immune responses. Immunity. 2021;54:132\u2013e1509. https:\/\/doi.org\/10.1016\/J.IMMUNI.2020.11.003\/ATTACHMENT\/270C03F8-3202-49CD-9524-908915DF54A8\/MMC1.PDF","journal-title":"Immunity"},{"key":"2417_CR210","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0005-2760(92)90150-T","volume":"1125","author":"H Hattori","year":"1992","unstructured":"Hattori H, Uemura K, ichi, Ishihara H, Ogata H. Glycolipid of human pancreatic cancer; the appearance of neolacto-series (type 2 chain) glycolipid and the presence of incompatible blood group antigen in tumor tissues. Biochimica et biophysica acta (BBA) -. Lipids Lipid Metabolism. 1992;1125:21\u20137. https:\/\/doi.org\/10.1016\/0005-2760(92)90150-T","journal-title":"Lipids Lipid Metabolism"},{"key":"2417_CR211","doi-asserted-by":"publisher","unstructured":"Dong L, Cao Z, Chen M, Liu Y, Ma X, Lu Y et al. Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nat Commun 2024;15:1\u201319. https:\/\/doi.org\/10.1038\/s41467-024-51495-3","DOI":"10.1038\/s41467-024-51495-3"},{"key":"2417_CR212","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X","journal-title":"Lancet"},{"key":"2417_CR213","doi-asserted-by":"publisher","unstructured":"Loo K, Goldman DA, Panageas K, Callahan MK, Chapman PB, Momtaz P et al. Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint Blockade (ICB). 2021;39:9534\u20139534. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_SUPPL.9534","DOI":"10.1200\/JCO.2021.39.15_SUPPL.9534"},{"key":"2417_CR214","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-47425-y","volume":"15","author":"M Lauss","year":"2024","unstructured":"Lauss M, Phung B, Borch TH, Harbst K, Kaminska K, Ebbesson A, et al. Molecular patterns of resistance to immune checkpoint Blockade in melanoma. Nat Commun. 2024;15:1. https:\/\/doi.org\/10.1038\/s41467-024-47425-y","journal-title":"Nat Commun 2024"},{"key":"2417_CR215","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint Blockade immunotherapy in melanoma: Understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:5. https:\/\/doi.org\/10.1038\/s41590-022-01141-1","journal-title":"Nat Immunol 2022"},{"key":"2417_CR216","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman NA, Burchard PR, Dunne RF, Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022;40:2789\u2013805. https:\/\/doi.org\/10.1200\/JCO.21.02616\/ASSET\/IMAGES\/LARGE\/JCO.21.02616T2.JPEG.","journal-title":"J Clin Oncol"},{"key":"2417_CR217","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, de Carn\u00e9 Tr\u00e9cesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47:1083\u2013e10996. https:\/\/doi.org\/10.1016\/j.immuni.2017.11.016","journal-title":"Immunity"},{"key":"2417_CR218","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418\u201329. https:\/\/doi.org\/10.1016\/j.ccr.2012.01.007","journal-title":"Cancer Cell"},{"key":"2417_CR219","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.celrep.2017.06.062","volume":"20","author":"JE Jang","year":"2017","unstructured":"Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. Crosstalk between regulatory T cells and Tumor-Associated dendritic cells negates Anti-tumor immunity in pancreatic Cancer. Cell Rep. 2017;20:558\u201371. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.062","journal-title":"Cell Rep"},{"key":"2417_CR220","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nat. 2020;581:7806. https:\/\/doi.org\/10.1038\/s41586-020-2229-5","journal-title":"Nat 2020"},{"issue":"1","key":"2417_CR221","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","volume":"121","author":"E Karamitopoulou","year":"2019","unstructured":"Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer. 2019;121(1):121:5\u201314. https:\/\/doi.org\/10.1038\/s41416-019-0479-5","journal-title":"Br J Cancer 2019"},{"key":"2417_CR222","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0B013E31829FB7A2","volume":"36","author":"DT Le","year":"2013","unstructured":"Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36:382\u20139. https:\/\/doi.org\/10.1097\/CJI.0B013E31829FB7A2","journal-title":"J Immunother"},{"key":"2417_CR223","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMOA1200694\/","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of Anti\u2013PD-L1 antibody in patients with advanced Cancer. N Engl J Med. 2012;366:2455\u201365. https:\/\/doi.org\/10.1056\/NEJMOA1200694\/SUPPL_FILE\/NEJMOA1200694_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"key":"2417_CR224","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/SCIENCE.AAN6733\/SUPPL_FILE\/AAN6733_TABLES-S8-S9-S10.XLSX","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 Blockade. Sci (1979). 2017;357:409\u201313. https:\/\/doi.org\/10.1126\/SCIENCE.AAN6733\/SUPPL_FILE\/AAN6733_TABLES-S8-S9-S10.XLSX","journal-title":"Sci (1979)"},{"key":"2417_CR225","doi-asserted-by":"publisher","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science (1979) 2015;348:56\u201361. https:\/\/doi.org\/10.1126\/SCIENCE.AAA8172","DOI":"10.1126\/SCIENCE.AAA8172"},{"key":"2417_CR226","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255\/659934","volume":"75","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers basedon T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139\u201345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0255\/659934\/P\/CLASSIFYING-CANCERS-BASED-ON-T-CELL-INFILTRATION.","journal-title":"Cancer Res"},{"key":"2417_CR227","doi-asserted-by":"publisher","first-page":"7681","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran VP, \u0141uksza M, Zhao JN, Makarov V, Moral JA, Remark R, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nat. 2017;551:7681. https:\/\/doi.org\/10.1038\/nature24462","journal-title":"Nat 2017"},{"key":"2417_CR228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:1. https:\/\/doi.org\/10.1038\/ncomms12632","journal-title":"Nat Commun 2016"},{"key":"2417_CR229","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","volume":"33","author":"CW Li","year":"2018","unstructured":"Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, et al. Eradication of Triple-Negative breast Cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33:187\u2013e20110. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.009","journal-title":"Cancer Cell"},{"key":"2417_CR230","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41418-023-01188-z","volume":"30","author":"H Ma","year":"2023","unstructured":"Ma H, Chen X, Mo S, Zhang Y, Mao X, Chen J, et al. Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma. Cell Death Differ. 2023;30:8. https:\/\/doi.org\/10.1038\/s41418-023-01188-z","journal-title":"Cell Death Differ 2023"},{"key":"2417_CR231","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41416-020-0772-3","volume":"122","author":"R Gupta","year":"2020","unstructured":"Gupta R, Leon F, Thompson CM, Nimmakayala R, Karmakar S, Nallasamy P, et al. Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis. Br J Cancer. 2020;122:11. https:\/\/doi.org\/10.1038\/s41416-020-0772-3","journal-title":"Br J Cancer 2020"},{"key":"2417_CR232","doi-asserted-by":"publisher","unstructured":"Kong K, Zhao Y, Xia L, Jiang H, Xu M, Zheng J. B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma. Oncol Lett. 2021;21. https:\/\/doi.org\/10.3892\/OL.2020.12420","DOI":"10.3892\/OL.2020.12420"},{"key":"2417_CR233","doi-asserted-by":"publisher","first-page":"24735","DOI":"10.1074\/jbc.272.40.24735","volume":"272","author":"K Orford","year":"1997","unstructured":"Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of \u03b2- Catenin. J Biol Chem. 1997;272:24735\u20138. https:\/\/doi.org\/10.1074\/jbc.272.40.24735","journal-title":"J Biol Chem"},{"key":"2417_CR234","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1093\/EMBOJ\/16.13.3797","volume":"16","author":"H Aberle","year":"1997","unstructured":"Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. \u03b2-catenin is a target for the ubiquitin\u2013proteasome pathway. EMBO J. 1997;16:3797\u2013804. https:\/\/doi.org\/10.1093\/EMBOJ\/16.13.3797","journal-title":"EMBO J"},{"key":"2417_CR235","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/sj.onc.1207389","volume":"23","author":"SY Fuchs","year":"2004","unstructured":"Fuchs SY, Spiegelman VS, Kumar KGS. The many faces of \u03b2-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene. 2004;23:11. https:\/\/doi.org\/10.1038\/sj.onc.1207389","journal-title":"Oncogene 2004"},{"key":"2417_CR236","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","volume":"42","author":"G Mucciolo","year":"2024","unstructured":"Mucciolo G, Araos Henr\u00edquez J, Jihad M, Pinto Teles S, Manansala JS, Li W, et al. EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell. 2024;42:101\u2013e11811. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.002","journal-title":"Cancer Cell"},{"key":"2417_CR237","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1172\/JCI126022","volume":"129","author":"LC Chan","year":"2019","unstructured":"Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, et al. IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129:3324\u201338. https:\/\/doi.org\/10.1172\/JCI126022","journal-title":"J Clin Invest"},{"key":"2417_CR238","doi-asserted-by":"publisher","unstructured":"Zhang X, Huang X, Xu J, Li E, Lao M, Tang T et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nature Communications. 2021 12:1 2021;12:1\u201317. https:\/\/doi.org\/10.1038\/s41467-021-24769-3","DOI":"10.1038\/s41467-021-24769-3"},{"key":"2417_CR239","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","volume":"71","author":"JH Cha","year":"2018","unstructured":"Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin promotes antitumor immunity via Endoplasmic-Reticulum-Associated degradation of PD-L1. Mol Cell. 2018;71:606\u2013e6207. https:\/\/doi.org\/10.1016\/j.molcel.2018.07.030","journal-title":"Mol Cell"},{"key":"2417_CR240","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint Blockade cancer immunotherapy targets tumour-specific mutant antigens. Nat. 2014;515:7528. https:\/\/doi.org\/10.1038\/nature13988","journal-title":"Nat 2014"},{"key":"2417_CR241","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nat. 2014;515:7528. https:\/\/doi.org\/10.1038\/nature14011","journal-title":"Nat 2014"},{"key":"2417_CR242","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nat. 2014;515:7528. https:\/\/doi.org\/10.1038\/nature13904","journal-title":"Nat 2014"},{"key":"2417_CR243","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting Immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nat. 2014;515:7528. https:\/\/doi.org\/10.1038\/nature14001","journal-title":"Nat 2014"},{"key":"2417_CR244","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMOA1802357\/SUPPL_FILE","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMOA1802357\/SUPPL_FILE\/NEJMOA1802357_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"key":"2417_CR245","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMOA1716078\/SUPPL_FILE","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in resectable lung Cancer. N Engl J Med. 2018;378:1976\u201386. https:\/\/doi.org\/10.1056\/NEJMOA1716078\/SUPPL_FILE\/NEJMOA1716078_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"key":"2417_CR246","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-60761-783-9_7\/COVER","volume":"657","author":"BS Lee","year":"2010","unstructured":"Lee BS, Huang JS, Jayathilaka GDLP, Lateef SS, Gupta S. Production of antipeptide antibodies. Methods Mol Biol. 2010;657:93\u2013108. https:\/\/doi.org\/10.1007\/978-1-60761-783-9_7\/COVER","journal-title":"Methods Mol Biol"},{"key":"2417_CR247","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","volume":"36","author":"HH Lee","year":"2019","unstructured":"Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, et al. Removal of N-Linked glycosylation enhances PD-L1 detection and predicts Anti-PD-1\/PD-L1 therapeutic efficacy. Cancer Cell. 2019;36:168\u2013e1784. https:\/\/doi.org\/10.1016\/j.ccell.2019.06.008","journal-title":"Cancer Cell"},{"key":"2417_CR248","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12929-020-00670-X\/FIGURES\/3","volume":"27","author":"YN Wang","year":"2020","unstructured":"Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci. 2020;27:1\u201311. https:\/\/doi.org\/10.1186\/S12929-020-00670-X\/FIGURES\/3","journal-title":"J Biomed Sci"},{"key":"2417_CR249","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-19-3133\/653933\/","volume":"80","author":"L Sun","year":"2020","unstructured":"Sun L, Li CW, Chung EM, Yang R, Kim YS, Park AH, et al. Targeting glycosylated PD-1 induces potent antitumor immunity. Cancer Res. 2020;80:2298\u2013310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3133\/653933\/AM\/TARGETING-GLYCOSYLATED-PD-1-INDUCES-POTENT-ANTI.","journal-title":"Cancer Res"},{"key":"2417_CR250","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41416-022-01966-5","volume":"127","author":"C Davidson","year":"2022","unstructured":"Davidson C, Taggart D, Sims AH, Lonergan DW, Canel M, Serrels A. FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer. Br J Cancer. 2022;127:10. https:\/\/doi.org\/10.1038\/s41416-022-01966-5","journal-title":"Br J Cancer 2022"},{"key":"2417_CR251","doi-asserted-by":"publisher","unstructured":"Wang H, Yao H, Li C, Liang L, Zhang Y, Shi H, et al., et al. PD-L2 expression in colorectal cancer: independent prognostic effect and targetability by deglycosylation. Oncoimmunology. 2017;6. https:\/\/doi.org\/10.1080\/2162402X.2017.1327494","DOI":"10.1080\/2162402X.2017.1327494"},{"key":"2417_CR252","doi-asserted-by":"publisher","first-page":"e002699","DOI":"10.1136\/JITC-2021-002699","volume":"9","author":"Y Xu","year":"2021","unstructured":"Xu Y, Gao Z, Hu R, Wang Y, Wang Y, Su Z, et al. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. J Immunother Cancer. 2021;9:e002699. https:\/\/doi.org\/10.1136\/JITC-2021-002699","journal-title":"J Immunother Cancer"},{"key":"2417_CR253","doi-asserted-by":"publisher","unstructured":"Liang C, Song W, Gu J. Significance of FUT8 in pancreatic Cancer and others. Glycosignals in cancer: molecular assembly and recognition. Second Ed. 2023;105\u201324. https:\/\/doi.org\/10.1007\/978-981-19-7732-9_6","DOI":"10.1007\/978-981-19-7732-9_6"},{"key":"2417_CR254","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/35105024","volume":"1","author":"ML Alegre","year":"2001","unstructured":"Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Reviews Immunol. 2001;1:3. https:\/\/doi.org\/10.1038\/35105024","journal-title":"Nat Reviews Immunol 2001"},{"key":"2417_CR255","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1038\/35055582","volume":"409","author":"M Demetriou","year":"2001","unstructured":"Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nat. 2001;409:6821. https:\/\/doi.org\/10.1038\/35055582","journal-title":"Nat 2001"},{"key":"2417_CR256","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cell.2007.01.049","volume":"129","author":"KS Lau","year":"2007","unstructured":"Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, et al. Complex N-Glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007;129:123\u201334. https:\/\/doi.org\/10.1016\/j.cell.2007.01.049","journal-title":"Cell"},{"key":"2417_CR257","doi-asserted-by":"publisher","first-page":"C006","DOI":"10.1158\/1538-7445.PANCA22-C006","volume":"82","author":"E Hollander","year":"2022","unstructured":"Hollander E, Stanger B. Abstract C006: loss of the MGAT5 glycosyltransferase sensitizes pancreatic tumor cells to immune clearance. Cancer Res. 2022;82:C006\u2013006. https:\/\/doi.org\/10.1158\/1538-7445.PANCA22-C006","journal-title":"Cancer Res"},{"key":"2417_CR258","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.4049\/JIMMUNOL.180.5.3158","volume":"180","author":"D Li","year":"2008","unstructured":"Li D, Li Y, Wu X, Li Q, Yu J, Gen J, et al. Knockdown of Mgat5 inhibits breast Cancer cell growth with activation of CD4\u2009+\u2009T cells and macrophages. J Immunol. 2008;180:3158\u201365. https:\/\/doi.org\/10.4049\/JIMMUNOL.180.5.3158","journal-title":"J Immunol"},{"key":"2417_CR259","doi-asserted-by":"publisher","first-page":"310936","DOI":"10.3389\/FIMMU.2017.01467\/BIBTEX","volume":"8","author":"S Zumerle","year":"2017","unstructured":"Zumerle S, Molon B, Viola A. Membrane rafts in T cell activation: A spotlight on CD28 costimulation. Front Immunol. 2017;8:310936. https:\/\/doi.org\/10.3389\/FIMMU.2017.01467\/BIBTEX","journal-title":"Front Immunol"},{"key":"2417_CR260","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/J.BBRC.2004.03.012","volume":"317","author":"SL Ma","year":"2004","unstructured":"Ma SL, Zhu WX, Guo QL, Liu YC, Xu MQ. CD28 T cell costimulatory receptor function is negatively regulated by N-linked carbohydrates. Biochem Biophys Res Commun. 2004;317:60\u20137. https:\/\/doi.org\/10.1016\/J.BBRC.2004.03.012","journal-title":"Biochem Biophys Res Commun"},{"key":"2417_CR261","doi-asserted-by":"publisher","first-page":"7139","DOI":"10.1038\/nature05815","volume":"446","author":"GW Hart","year":"2007","unstructured":"Hart GW, Housley MP, Slawson C. Cycling of O-linked \u03b2-N-acetylglucosamine on nucleocytoplasmic proteins. Nat. 2007;446:7139. https:\/\/doi.org\/10.1038\/nature05815","journal-title":"Nat 2007"},{"key":"2417_CR262","doi-asserted-by":"publisher","unstructured":"Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science (1979) 2012;337:975\u201380. https:\/\/doi.org\/10.1126\/SCIENCE.1222278\/SUPPL_FILE\/YI.W.SM.PDF","DOI":"10.1126\/SCIENCE.1222278\/SUPPL_FILE\/YI.W.SM.PDF"},{"key":"2417_CR263","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrm.2017.22","volume":"18","author":"X Yang","year":"2017","unstructured":"Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Reviews Mol Cell Biology. 2017;18:7. https:\/\/doi.org\/10.1038\/nrm.2017.22","journal-title":"Nat Reviews Mol Cell Biology 2017"},{"key":"2417_CR264","doi-asserted-by":"publisher","first-page":"e2216796120","DOI":"10.1073\/PNAS.2216796120\/SUPPL_FILE","volume":"120","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, Wang H, Chai S, Xu L, Lin B, Yi W, et al. O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation. Proc Natl Acad Sci U S A. 2023;120:e2216796120. https:\/\/doi.org\/10.1073\/PNAS.2216796120\/SUPPL_FILE\/PNAS.2216796120.SAPP.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2417_CR265","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y, Xu D, Liao MM, Sun Y, Bao WD, Yao F, et al. Barriers and opportunities in pancreatic cancer immunotherapy. Npj Precision Oncol. 2024;8:1. https:\/\/doi.org\/10.1038\/s41698-024-00681-z","journal-title":"Npj Precision Oncol 2024"},{"key":"2417_CR266","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.11923\/SUPPL_FILE","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic Cancer. N Engl J Med. 2011;364:1817\u201325. https:\/\/doi.org\/10.1056\/NEJMOA1011923\/SUPPL_FILE\/NEJMOA1011923_DISCLOSURES.PDF.","journal-title":"N Engl J Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02417-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02417-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02417-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T06:03:42Z","timestamp":1754373822000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02417-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":266,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2417"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02417-4","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}